{"gene":"CEACAM5","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":1987,"finding":"The primary structure of CEACAM5 (CEA) was determined from cDNA cloning, revealing it is synthesized as a precursor with a signal peptide followed by 668 amino acids comprising an N-terminal domain, three highly homologous repeated domains of 178 amino acids each (containing four conserved cysteines and multiple N-glycosylation sites per repeat), and a C-terminal hydrophobic membrane-anchoring domain, establishing CEA as a member of the immunoglobulin superfamily.","method":"cDNA cloning and sequencing, in vitro transcription/translation, cell transfection with immunoprecipitation","journal":"Biochemical and biophysical research communications / Molecular and cellular biology / PNAS","confidence":"High","confidence_rationale":"Tier 1 — independently replicated across three labs in the same year using full-length cDNA cloning and sequencing","pmids":["3814146","3670312","3033671"],"is_preprint":false},{"year":1989,"finding":"CEACAM5 (CEA) and NCA expressed on CHO cell surfaces function as calcium-independent cell adhesion molecules through both homophilic (CEA-CEA) and heterophilic (CEA-NCA) interactions; CEA-CEA homophilic adhesion was the strongest, and all interactions were completely blocked by anti-CEA Fab' fragments.","method":"CHO cell transfection with CEA/NCA cDNAs, cell aggregation assay, 51Cr-labeled cell adhesion assay with antibody inhibition","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 — direct functional adhesion assay with genetic expression system and antibody blockade controls","pmids":["2803308"],"is_preprint":false},{"year":1989,"finding":"During differentiation of HT29-D4 colon cancer cells, CEA expression becomes restricted exclusively to the apical cell surface of polarized epithelial monolayers, and CEA release is vectorially directed toward the apical compartment; undifferentiated cells express and release only small amounts of CEA.","method":"Independent radioiodination of apical vs. basolateral domains of polarized monolayers followed by immunoprecipitation; permeable chamber culture assays","journal":"Journal of cellular physiology","confidence":"High","confidence_rationale":"Tier 2 — direct domain-specific labeling experiment with functional polarization readout","pmids":["2674159"],"is_preprint":false},{"year":1990,"finding":"The CEA gene promoter region (~400 nucleotides upstream of the translational start) contains cis-acting sequences sufficient for cell-type-specific expression, showing ~9-fold higher activity in CEA-producing adenocarcinoma cells (SW403) than in non-producing HeLa cells; the promoter lacks classic TATA or CAAT boxes.","method":"Promoter-indicator gene transfection assays in CEA-producing vs. non-producing cell lines","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — direct promoter functional assay with cell-type specificity control","pmids":["2342461"],"is_preprint":false},{"year":1983,"finding":"CEA clearance from circulation is mediated by the liver: removal of as few as two sialic acid residues exposes terminal galactosyl residues recognized by a hepatocyte plasma membrane receptor (hepatic binding protein), leading to rapid uptake and lysosomal catabolism; ~70% of intact 125I-CEA is cleared by the liver within 1 hour, and ~10% appears in bile.","method":"Isolated perfused liver experiments, 125I-labeled CEA biodistribution, enzymatic desialylation","journal":"Digestive diseases and sciences","confidence":"High","confidence_rationale":"Tier 2 — direct biochemical experiment with isotope tracing and enzymatic manipulation","pmids":["6337795"],"is_preprint":false},{"year":2000,"finding":"CEACAM5 (CEA) and CEACAM6 function as general inhibitors of anoikis (apoptosis triggered by loss of extracellular matrix anchorage) when overexpressed in multiple cell types; CEACAM1, by contrast, does not inhibit anoikis, identifying a specific anti-apoptotic function unique to GPI-anchored CEA family members.","method":"Stable overexpression of CEA/CEACAM6/CEACAM1 in multiple cell lines, anoikis assays in suspension culture","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — multiple cell systems tested with appropriate family-member controls","pmids":["10910050"],"is_preprint":false},{"year":2005,"finding":"CEACAM5 on tumor cells interacts heterophilically with CEACAM1 on NK cells, and this heterophilic interaction inhibits NK cell-mediated cytotoxicity against tumor cells; the N-terminal domains of both CEACAM1 and CEA are necessary but not sufficient for this interaction, and additional domains are required to regulate cis vs. trans interactions.","method":"Functional NK killing assays, binding assays with domain mutants, co-incubation experiments","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal binding and functional assays with domain dissection","pmids":["15905509"],"is_preprint":false},{"year":2007,"finding":"CEACAM5 (CEA) and CEACAM6 co-cluster with integrin α5β1 on the cell surface, enhance integrin α5β1 binding to fibronectin without altering surface integrin levels, promote fibronectin matrix assembly forming a polymerized fibronectin 'cocoon' around cells, and thereby inhibit cellular differentiation and anoikis; disruption with anti-fibronectin or anti-integrin α5β1 antibodies restores differentiation and anoikis.","method":"Confocal microscopy, specific antibody co-clustering experiments, fibronectin binding and matrix assembly assays, differentiation/anoikis rescue experiments","journal":"Journal of cellular physiology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods with functional rescue experiments","pmids":["17167768"],"is_preprint":false},{"year":2008,"finding":"CEA (CEACAM5) functions as an E-selectin and L-selectin ligand on colon carcinoma cells, carrying sialofucosylated glycans that support rolling adhesion under flow conditions; CEA and CD44 variant isoforms cooperate to mediate tumor cell adhesion to E- and L-selectin at elevated shear stresses, providing a potential mechanism for hematogenous metastasis.","method":"Immunoaffinity chromatography, tandem mass spectrometry identification, bead-coating with purified CEA, blot rolling and flow-based adhesion assays, stable CD44 knockdown cell lines","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — biochemical purification, MS identification, reconstituted adhesion assay under flow, genetic knockdown","pmids":["18375392"],"is_preprint":false},{"year":2008,"finding":"CEA (CEACAM5) acts as an inducer of CEACAM1-mediated apoptosis in HT29 colon cancer cells, an effect dependent on CEACAM1 cell-surface abundance; CEACAM1-mediated apoptosis triggered by CEA involves dual cleavage of CEACAM1 (at both intracellular and extracellular sites), caspase-1 and caspase-3 activation, and non-caspase proteases.","method":"CEA treatment of HT29 cells, CEACAM1 cleavage analysis, caspase activation assays, HEK293/Jurkat cell models","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — multiple mechanistic readouts in single study; single lab","pmids":["18278069"],"is_preprint":false},{"year":2013,"finding":"CEACAM5 (identified as the epithelial glycoprotein gp180) binds CD8α through its N-terminal domain in a glycosylation-dependent manner, activates CD8-associated Lck kinase, and is the only CEACAM family member that interacts with CD1d through its B3 domain; CEACAM5-activated CD8+ T cells acquire suppressor activity against CD4+ T cell proliferation in vitro in the presence of IL-15 or IL-7.","method":"Protein purification and sequence analysis, binding assays with domain deletion mutants, Lck activation assays, T-cell suppression assays, confocal co-localization","journal":"Mucosal immunology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple binding and functional assays; single lab","pmids":["24104458"],"is_preprint":false},{"year":2016,"finding":"H. pylori outer membrane protein HopQ binds the N-terminal IgV-like domain of CEACAM5 (and CEACAM1, 3, 6) in a glycan-independent manner with high affinity (KD 23–268 nM), and this HopQ-CEACAM interaction is required for translocation of the virulence factor CagA into host cells via the cag type IV secretion system and enhances IL-8 release; a β-hairpin insertion domain (HopQ-ID) in HopQ mediates CEACAM binding.","method":"Crystal structure of HopQ, KD measurements, genetic introduction of CEACAM constructs into AZ-521 cells, CagA phosphorylation assays, IL-8 release assays, competitive peptide inhibition","journal":"Nature microbiology","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus functional validation in multiple complementary assays, independently replicated in two concurrent papers","pmids":["27748768","27748756"],"is_preprint":false},{"year":2018,"finding":"Expression of CEACAM1 or CEACAM5 (but not CEACAM6) in CEACAM-deficient AZ-521 cells is sufficient to restore H. pylori T4SS-mediated CagA injection and phosphorylation, and is accompanied by tyrosine dephosphorylation of cytoskeletal proteins vinculin and cortactin; the T4SS delivery pathway requires both integrin-β1 and CEACAM1/CEACAM5.","method":"Genetic complementation of CEACAM-deficient cells, CagA phosphorylation assays, immunoblotting for vinculin/cortactin dephosphorylation","journal":"Cellular microbiology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic complementation with specific molecular readouts; single lab","pmids":["30321907"],"is_preprint":false},{"year":2016,"finding":"Bacterial engagement of CEA (CEACAM5) by neisserial Opa proteins or uropathogenic E. coli Afa/Dr adhesins alters gene expression, increases integrin activity, promotes matrix adhesion of cervical and vaginal epithelial cells, and suppresses exfoliation to promote urogenital tract colonization; these CEA-triggered events were demonstrated to be sufficient for colonization suppression using CEA-transgenic vs. wildtype mouse in vivo comparison.","method":"Heterologous Opa expression in non-pathogenic E. coli, in vitro gene expression and integrin activity assays, CEA-transgenic mouse colonization model vs. wildtype, CEACAM-binding adhesin deletion mutants","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal in vitro and in vivo methods with genetic controls","pmids":["27171273"],"is_preprint":false},{"year":2018,"finding":"CEACAM5 is a direct transcriptional target of HIF1α, and FBW7 suppresses CEACAM5 expression and colorectal cancer cell migration through a HIF1α-dependent mechanism; ChIP and luciferase assays demonstrated HIF1α binding to the CEACAM5 promoter, and FBW7 regulates HIF1α protein levels to control CEACAM5 expression.","method":"Luciferase reporter assay, chromatin immunoprecipitation (ChIP), loss-of-function and gain-of-function experiments, in vitro migration assays, gene expression microarray","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and luciferase assays with functional validation; single lab","pmids":["29910683"],"is_preprint":false},{"year":2018,"finding":"CEACAM5 overexpression drives metastatic colonization by promoting mesenchymal-to-epithelial transition (MET), enriching for an epithelial gene expression pattern, and facilitating tumor outgrowth at metastatic sites; an inverse correlation between CEACAM5 and the mesenchymal marker vimentin was demonstrated in patient lung metastases.","method":"In vivo serial passaging of lung metastases, high-throughput gain-of-function screen in vivo, gene expression analysis, patient tissue validation","journal":"NPJ breast cancer","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo functional screen with molecular mechanism (MET promotion); single lab","pmids":["29736411"],"is_preprint":false},{"year":2020,"finding":"CEACAM5 expression in neuroendocrine prostate cancer (NEPC) is driven by the pioneer transcription factor ASCL1, which promotes neuroendocrine reprogramming associated with increased chromatin accessibility at the CEACAM5 core promoter; CEACAM5 depletion or antibody-drug conjugate (labetuzumab govitecan) treatment induces DNA damage and antitumor responses in CEACAM5+ models.","method":"Neuroendocrine transdifferentiation assay, chromatin accessibility analysis (ATAC-seq), patient-derived xenograft models, multiplex immunofluorescence","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — epigenomic and functional validation of ASCL1-driven CEACAM5 regulation; single lab","pmids":["33199493"],"is_preprint":false},{"year":2020,"finding":"CEACAM5 depletion in NSCLC cells inhibits proliferation and migration by activating p38-Smad2/3 signaling, and CEACAM5 suppresses this pathway to promote tumor progression in vitro and in vivo.","method":"siRNA knockdown, MTT assay, wound healing assay, immunoblotting for p38-Smad2/3 pathway, xenograft mouse model","journal":"The Journal of international medical research","confidence":"Low","confidence_rationale":"Tier 3 — single lab, single knockdown approach with pathway western blots but no rescue or epistasis confirmation","pmids":["32993395"],"is_preprint":false},{"year":2011,"finding":"In colorectal cancer tissue, CEACAM5 (CEA) carries distinct tumor-associated carbohydrate modifications compared to normal tissue, including high levels of Lewis X and Lewis Y blood-group antigens that enable recognition and binding by the human C-type lectin DC-SIGN on antigen-presenting cells; increased mannose and branched N-glycans correlate with Galectin-3 binding.","method":"CEA/MUC1 capture ELISA with plant and human C-type lectins, 48-patient matched normal/tumor comparison","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 — systematic comparative glycan profiling with multiple lectins on matched patient samples","pmids":["21823122"],"is_preprint":false},{"year":2024,"finding":"CEA (CEACAM5) activates the PI3K/AKT pathway by directly binding to KRT1 (keratin 1) at the cell surface, and this CEA-KRT1 interaction promotes oxaliplatin resistance in gastric cancer cells; the interaction was confirmed by Co-IP, GST pull-down, and immunofluorescence colocalization, and a small molecule inhibitor (evacetrapib) competitively inhibits this interaction to restore drug sensitivity.","method":"Co-immunoprecipitation, GST pull-down, immunofluorescence colocalization, proteomic analysis, virtual screening and surface plasmon resonance for inhibitor validation, CCK8/colony formation/xenograft assays, organoid model","journal":"Drug resistance updates","confidence":"Medium","confidence_rationale":"Tier 2 — reciprocal binding assays (Co-IP, GST pulldown) with functional validation; single lab","pmids":["39644827"],"is_preprint":false},{"year":2024,"finding":"Under hypoxia, pNET cells package CEACAM5 into exosomes; exosomal CEACAM5 induces M2 polarization of tumor-associated macrophages (TAM) through activation of the MAPK signaling pathway, and M2-polarized TAM in turn enhance pNET cell migration and invasion.","method":"Exosome isolation and characterization, co-culture experiments, MAPK pathway inhibition, macrophage polarization assays, in vitro migration/invasion assays","journal":"FASEB journal","confidence":"Low","confidence_rationale":"Tier 3 — mechanistic pathway identified but single lab, no genetic rescue confirming CEACAM5 specificity in exosomes","pmids":["38923643"],"is_preprint":false},{"year":2005,"finding":"Antibody Fabs targeting the N-terminal (MN-3) or A1B1 (MN-15) domains shared by CEACAM5 and CEACAM6 inhibit tumor cell migration, invasion through extracellular matrix, and adhesion to endothelial cells; MN-15 Fab also reduced adhesion to fibronectin in some cell lines; MN-3 and MN-15 Fabs showed antimetastatic effects in vivo in a human colonic micrometastasis model.","method":"Migration assay, Matrigel invasion assay, tumor-endothelial cell adhesion assay, fibronectin/vitronectin/laminin/collagen adhesion assays, in vivo mouse metastasis model","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — multiple in vitro adhesion/invasion assays plus in vivo validation; single lab","pmids":["16204051"],"is_preprint":false},{"year":2013,"finding":"Serpin B5 (maspin) physically interacts with CEA (CEACAM5) in colorectal cancer cells; this interaction was identified by 2D-gel proteomics of CEA-suppressed cells, confirmed by co-immunoprecipitation and confocal colocalization, and serpin B5 protein levels positively correlate with CEA levels in colon cancer cell lines and patient blood.","method":"Two-dimensional gel electrophoresis, MALDI-MS, co-immunoprecipitation, confocal microscopy colocalization, western blot, ELISA","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 3 — Co-IP and colocalization confirmed, but functional consequence of CEA-serpin B5 interaction not fully mechanistically resolved","pmids":["24114705"],"is_preprint":false},{"year":2007,"finding":"In CEA/CEACAM6 transgenic mice expressing these molecules at levels found in human colorectal carcinomas, colonocyte surface integrin α5 levels and AKT activation progressively increase with CEA/CEACAM6 expression, and colons show progressive hyperplasia, increased crypt fission, inhibition of differentiation and anoikis/apoptosis, culminating in a continuous mosaic of severe hyperplasia, dysplasia and serrated adenomatous morphology.","method":"Human CEA/CEACAM6 genomic transgenic mouse model with titrated expression, histology, immunostaining for integrin α5 and phospho-AKT","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo genetic model with molecular pathway measurements; single lab","pmids":["18159236"],"is_preprint":false}],"current_model":"CEACAM5 (CEA) is a GPI-anchored immunoglobulin superfamily glycoprotein that functions as a homophilic and heterophilic cell adhesion molecule; it inhibits anoikis by enhancing integrin α5β1–fibronectin interaction and fibronectin matrix assembly, evades NK-mediated immune surveillance through heterophilic interaction with inhibitory CEACAM1 on NK cells, promotes metastasis partly by acting as an E/L-selectin ligand and by driving mesenchymal-to-epithelial transition, activates CD8+ suppressor T cells via CD8α and CD1d binding, serves as a receptor for bacterial pathogens (H. pylori HopQ, Afa/Dr adhesins) enabling CagA translocation and suppression of epithelial exfoliation, is transcriptionally regulated by HIF1α and ASCL1 via chromatin remodeling at its promoter, and can activate PI3K/AKT signaling through direct binding to KRT1, promoting drug resistance."},"narrative":{"teleology":[{"year":1983,"claim":"Establishing the metabolic fate of circulating CEA resolved how serum levels are regulated: the liver clears CEA via a galactose-recognizing receptor after partial desialylation, followed by lysosomal degradation.","evidence":"Isolated perfused liver experiments with ¹²⁵I-CEA and enzymatic desialylation","pmids":["6337795"],"confidence":"High","gaps":["Identity of the specific hepatic lectin receptor was not molecularly defined","Whether desialylation occurs in vivo enzymatically or non-enzymatically was not resolved"]},{"year":1987,"claim":"cDNA cloning revealed CEACAM5's primary structure—an Ig superfamily member with a signal peptide, N-terminal IgV-like domain, six IgC2-like domains arranged in three repeats, and a GPI-anchor signal—providing the molecular framework for all subsequent functional studies.","evidence":"Independent cDNA cloning and sequencing by three laboratories with in vitro translation and cell transfection","pmids":["3814146","3670312","3033671"],"confidence":"High","gaps":["Three-dimensional structure not determined at this stage","GPI anchorage inferred from hydrophobic C-terminal sequence but not biochemically confirmed here"]},{"year":1989,"claim":"Demonstrating that CEACAM5 mediates both homophilic (CEA-CEA) and heterophilic (CEA-NCA/CEACAM6) adhesion when expressed on cell surfaces established it as a bona fide cell adhesion molecule and explained its family-level binding versatility.","evidence":"CHO cell transfection, ⁵¹Cr-labeled aggregation assay with anti-CEA Fab' blockade; parallel polarized-cell localization studies","pmids":["2803308","2674159"],"confidence":"High","gaps":["Which domains mediate homophilic vs. heterophilic binding was not mapped","Apical restriction mechanism not elucidated"]},{"year":2000,"claim":"The discovery that CEACAM5 (and CEACAM6 but not CEACAM1) inhibits anoikis shifted understanding from a passive adhesion molecule to an active anti-apoptotic effector, implicating it in anchorage-independent tumor survival.","evidence":"Overexpression of CEA family members in multiple cell lines with anoikis assays in suspension culture","pmids":["10910050"],"confidence":"High","gaps":["Downstream signaling pathway mediating anoikis inhibition was not identified","Whether GPI anchorage per se is the distinguishing feature from CEACAM1 was untested"]},{"year":2005,"claim":"Two parallel advances revealed CEACAM5's roles in immune evasion and metastatic behavior: heterophilic binding to CEACAM1 on NK cells inhibits anti-tumor cytotoxicity, while antibody targeting of CEACAM5 N-terminal/A1B1 domains suppresses tumor migration, invasion, and in vivo metastasis.","evidence":"NK killing assays with domain mutants; Matrigel invasion, endothelial adhesion, and in vivo micrometastasis model with anti-CEA Fabs","pmids":["15905509","16204051"],"confidence":"High","gaps":["Signaling pathway downstream of CEACAM1 ITIM activation by CEA not resolved","Whether anti-CEA Fab effects are solely through CEACAM5 or also CEACAM6 was not fully distinguished"]},{"year":2007,"claim":"Identification that CEACAM5 co-clusters with integrin α5β1 to enhance fibronectin binding and matrix assembly provided the molecular mechanism for anoikis inhibition and differentiation block, validated in transgenic mice showing dose-dependent colonic hyperplasia and AKT activation.","evidence":"Confocal co-clustering, fibronectin matrix assembly assays, antibody rescue of anoikis; CEA/CEACAM6 transgenic mouse histology and phospho-AKT immunostaining","pmids":["17167768","18159236"],"confidence":"High","gaps":["Whether CEA-integrin interaction is direct or lipid raft-mediated was unresolved","Transgenic model used combined CEA/CEACAM6 expression, complicating attribution to CEACAM5 alone"]},{"year":2008,"claim":"CEACAM5 was shown to carry sialofucosylated glycans that function as E/L-selectin ligands under flow, explaining how circulating tumor cells engage vascular endothelium during hematogenous metastasis; separately, soluble CEA was found to trigger CEACAM1-dependent apoptosis through caspase-1/3 activation.","evidence":"Selectin blot-rolling and flow adhesion assays with purified CEA-coated beads and CD44 knockdown cells; CEA treatment of HT29 cells with caspase and CEACAM1 cleavage analysis","pmids":["18375392","18278069"],"confidence":"High","gaps":["Whether CEA-selectin interaction is quantitatively significant relative to other selectin ligands in vivo is unknown","CEACAM1-mediated apoptosis induction by CEA not confirmed outside the HT29 system"]},{"year":2011,"claim":"Characterization of tumor-associated glycan modifications on CEACAM5 (Lewis X/Y, increased mannose) revealed how tumor-derived CEA engages DC-SIGN on antigen-presenting cells, linking aberrant glycosylation to immune modulation.","evidence":"Lectin capture ELISA on matched normal/tumor tissue from 48 patients","pmids":["21823122"],"confidence":"Medium","gaps":["Functional consequence of DC-SIGN engagement by tumor CEA on immune response not tested","Whether glycan changes are specific to CEACAM5 or general tumor-associated modifications unclear"]},{"year":2013,"claim":"Identification of CEACAM5 as the ligand for CD8α (through its N-domain, glycosylation-dependent) and CD1d (through its B3 domain) established its role in activating CD8+ suppressor T cells, providing a direct mechanism for CEA-mediated adaptive immune suppression in the gut.","evidence":"Domain deletion binding assays, Lck activation assays, T-cell suppression co-cultures with IL-15/IL-7","pmids":["24104458"],"confidence":"Medium","gaps":["In vivo relevance of CEA-CD8α/CD1d interaction for tumor immune evasion not demonstrated","Structural basis of the glycosylation-dependent CD8α binding not resolved"]},{"year":2016,"claim":"Crystal structures of H. pylori HopQ bound to CEACAM N-domains and in vivo CEA-transgenic mouse models demonstrated that CEACAM5 serves as a receptor exploited by pathogens: HopQ binding enables CagA translocation, while Afa/Dr adhesins suppress epithelial exfoliation to promote colonization.","evidence":"X-ray crystallography, KD measurements, CagA phosphorylation in CEACAM-reconstituted cells, CEA-transgenic vs. wildtype mouse colonization models","pmids":["27748768","27748756","27171273"],"confidence":"High","gaps":["Whether CEACAM5 versus CEACAM1/6 is the dominant receptor for HopQ in vivo is unresolved","Downstream signaling events in the epithelial cell upon bacterial CEACAM5 engagement are incompletely mapped"]},{"year":2018,"claim":"Transcriptional regulation of CEACAM5 was linked to HIF1α (with FBW7 as negative regulator) and separately to promotion of mesenchymal-to-epithelial transition at metastatic sites, connecting CEA upregulation under hypoxia to metastatic outgrowth.","evidence":"ChIP and luciferase assays for HIF1α binding to CEACAM5 promoter; in vivo serial passaging gain-of-function screen with gene expression profiling and patient tissue validation","pmids":["29910683","29736411"],"confidence":"Medium","gaps":["Whether HIF1α regulation of CEACAM5 operates in normal colon epithelium or only in tumor context is unknown","Mechanism by which CEACAM5 drives MET gene expression program not defined"]},{"year":2020,"claim":"ASCL1-driven chromatin remodeling at the CEACAM5 promoter was identified as the mechanism of CEACAM5 expression in neuroendocrine prostate cancer, expanding its relevance beyond adenocarcinomas to neuroendocrine lineages.","evidence":"ATAC-seq, neuroendocrine transdifferentiation assay, PDX models, antibody-drug conjugate treatment","pmids":["33199493"],"confidence":"Medium","gaps":["Whether ASCL1-CEACAM5 axis operates in other neuroendocrine tumors is untested","Functional role of CEACAM5 specifically in neuroendocrine cancer biology (vs. as a therapeutic target) is unclear"]},{"year":2024,"claim":"Discovery that CEACAM5 directly binds KRT1 to activate PI3K/AKT signaling provided a new mechanism for drug resistance, with a small-molecule inhibitor (evacetrapib) able to disrupt this interaction and restore oxaliplatin sensitivity.","evidence":"Co-IP, GST pull-down, SPR, immunofluorescence colocalization, organoid and xenograft models","pmids":["39644827"],"confidence":"Medium","gaps":["CEA-KRT1 interaction confirmed in gastric cancer only; generalizability to other CEACAM5-expressing cancers unknown","Structural basis of CEA-KRT1 binding not determined","Evacetrapib selectivity for CEA-KRT1 vs. other targets requires validation"]},{"year":null,"claim":"Key unresolved questions include the structural basis for CEACAM5's multivalent interactions (homophilic, CEACAM1, CD8α, CD1d, KRT1), how GPI-anchored CEACAM5 transmits intracellular signals in the absence of a cytoplasmic domain, and whether its immune-modulatory functions (NK inhibition, CD8+ T-cell suppression, DC-SIGN engagement) cooperate in vivo to shape anti-tumor immunity.","evidence":"","pmids":[],"confidence":"Low","gaps":["No full-length CEACAM5 structure available","Signaling intermediates linking GPI-anchored CEA to integrin/AKT activation remain unidentified","In vivo immune evasion models combining multiple CEA-immune receptor axes are lacking"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[1,7,8,21]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[6,10,11]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[7,19]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,2,7,8]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[4,8,18]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[20]}],"pathway":[{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[1,7,8]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[6,10,13,18]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,19,23]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[5,8,15,23]}],"complexes":[],"partners":["CEACAM1","CEACAM6","ITGA5","KRT1","CD8A","CD1D","SERPINB5"],"other_free_text":[]},"mechanistic_narrative":"CEACAM5 is a GPI-anchored immunoglobulin superfamily glycoprotein that mediates calcium-independent homophilic and heterophilic cell adhesion—including interactions with CEACAM1 and CEACAM6—and is expressed on the apical surface of polarized epithelial cells [PMID:2803308, PMID:2674159]. It inhibits anoikis by co-clustering with integrin α5β1 to enhance fibronectin binding and matrix assembly, activates PI3K/AKT signaling in part through direct interaction with KRT1, and promotes metastatic colonization by functioning as an E/L-selectin ligand and by driving mesenchymal-to-epithelial transition [PMID:17167768, PMID:18375392, PMID:29736411, PMID:39644827]. CEACAM5 modulates immune surveillance by engaging CEACAM1 on NK cells to inhibit cytotoxicity, by activating CD8+ suppressor T cells through CD8α and CD1d binding, and by serving as a receptor for bacterial pathogens including H. pylori HopQ and Afa/Dr adhesins that exploit it for CagA translocation and colonization [PMID:15905509, PMID:24104458, PMID:27748768, PMID:27171273]. Transcription of CEACAM5 is regulated by HIF1α and the pioneer factor ASCL1 through chromatin remodeling at its promoter [PMID:29910683, PMID:33199493]."},"prefetch_data":{"uniprot":{"accession":"P06731","full_name":"Cell adhesion molecule CEACAM5","aliases":["Carcinoembryonic antigen","CEA","Carcinoembryonic antigen-related cell adhesion molecule 5","CEA cell adhesion molecule 5","Meconium antigen 100"],"length_aa":702,"mass_kda":76.8,"function":"Cell surface glycoprotein that plays a role in cell adhesion, intracellular signaling and tumor progression (PubMed:10864933, PubMed:10910050, PubMed:2803308). Mediates homophilic and heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM6 (PubMed:2803308). Plays a role as an oncogene by promoting tumor progression; induces resistance to anoikis of colorectal carcinoma cells (PubMed:10910050) (Microbial infection) Receptor for E.coli Dr adhesins. Binding of E.coli Dr adhesins leads to dissociation of the homodimer","subcellular_location":"Cell membrane; Apical cell membrane; Cell surface","url":"https://www.uniprot.org/uniprotkb/P06731/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CEACAM5","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CEACAM5","total_profiled":1310},"omim":[{"mim_id":"619160","title":"CEA CELL ADHESION MOLECULE 7; CEACAM7","url":"https://www.omim.org/entry/619160"},{"mim_id":"613401","title":"VPS33B-INTERACTING PROTEIN, APICAL-BASOLATERAL POLARITY REGULATOR, SPE39 HOMOLOG; VIPAS39","url":"https://www.omim.org/entry/613401"},{"mim_id":"610650","title":"ADHESION-REGULATING MOLECULE 1; ADRM1","url":"https://www.omim.org/entry/610650"},{"mim_id":"608552","title":"VPS33B LATE ENDOSOME AND LYSOSOME ASSOCIATED; VPS33B","url":"https://www.omim.org/entry/608552"},{"mim_id":"163980","title":"CEA CELL ADHESION MOLECULE 6; CEACAM6","url":"https://www.omim.org/entry/163980"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"intestine","ntpm":920.3}],"url":"https://www.proteinatlas.org/search/CEACAM5"},"hgnc":{"alias_symbol":["CD66e"],"prev_symbol":["CEA"]},"alphafold":{"accession":"P06731","domains":[{"cath_id":"2.60.40.10","chopping":"38-142","consensus_level":"high","plddt":93.1206,"start":38,"end":142},{"cath_id":"2.60.40.10","chopping":"149-232","consensus_level":"medium","plddt":90.3557,"start":149,"end":232},{"cath_id":"2.60.40.10","chopping":"242-320","consensus_level":"medium","plddt":93.4584,"start":242,"end":320},{"cath_id":"2.60.40.10","chopping":"327-409","consensus_level":"high","plddt":89.2271,"start":327,"end":409},{"cath_id":"2.60.40.10","chopping":"420-497","consensus_level":"medium","plddt":93.1914,"start":420,"end":497},{"cath_id":"2.60.40.10","chopping":"505-587","consensus_level":"medium","plddt":90.4928,"start":505,"end":587},{"cath_id":"2.60.40.10","chopping":"598-676","consensus_level":"high","plddt":92.0041,"start":598,"end":676}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P06731","model_url":"https://alphafold.ebi.ac.uk/files/AF-P06731-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P06731-F1-predicted_aligned_error_v6.png","plddt_mean":87.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CEACAM5","jax_strain_url":"https://www.jax.org/strain/search?query=CEACAM5"},"sequence":{"accession":"P06731","fasta_url":"https://rest.uniprot.org/uniprotkb/P06731.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P06731/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P06731"}},"corpus_meta":[{"pmid":"10202129","id":"PMC_10202129","title":"The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues.","date":"1999","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/10202129","citation_count":969,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28660319","id":"PMC_28660319","title":"The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.","date":"2017","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/28660319","citation_count":313,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26861458","id":"PMC_26861458","title":"A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.","date":"2016","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/26861458","citation_count":279,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17201906","id":"PMC_17201906","title":"Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers.","date":"2007","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17201906","citation_count":203,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17400392","id":"PMC_17400392","title":"Cultured epithelial autograft (CEA) in burn treatment: three decades later.","date":"2007","source":"Burns : journal of the International Society for Burn Injuries","url":"https://pubmed.ncbi.nlm.nih.gov/17400392","citation_count":198,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16204051","id":"PMC_16204051","title":"Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen).","date":"2005","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16204051","citation_count":176,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9973217","id":"PMC_9973217","title":"Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus.","date":"1999","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9973217","citation_count":142,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6337795","id":"PMC_6337795","title":"Role of the liver in clearance and excretion of circulating carcinoembryonic antigen (CEA).","date":"1983","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/6337795","citation_count":100,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30062978","id":"PMC_30062978","title":"Carcinoembryonic Antigen (CEA) and Hepatic Metastasis in Colorectal Cancer: Update on Biomarker for Clinical and Biotechnological Approaches.","date":"2018","source":"Recent patents on biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/30062978","citation_count":99,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27622073","id":"PMC_27622073","title":"CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors.","date":"2016","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/27622073","citation_count":99,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10656428","id":"PMC_10656428","title":"Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine.","date":"2000","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/10656428","citation_count":93,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15905509","id":"PMC_15905509","title":"Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15905509","citation_count":89,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21823122","id":"PMC_21823122","title":"Differential glycosylation of MUC1 and CEACAM5 between normal mucosa and tumour tissue of colon cancer patients.","date":"2011","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21823122","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10632322","id":"PMC_10632322","title":"Bypassing immunization: optimized design of \"designer T cells\" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.","date":"1999","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/10632322","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6944526","id":"PMC_6944526","title":"Localization and concentration of carcinoembryonic antigen (CEA) in gastrointestinal tumors: correlation with CEA levels in plasma.","date":"1981","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/6944526","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21187495","id":"PMC_21187495","title":"Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients.","date":"2010","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21187495","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24327292","id":"PMC_24327292","title":"Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.","date":"2013","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/24327292","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33199493","id":"PMC_33199493","title":"Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer.","date":"2020","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/33199493","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10816511","id":"PMC_10816511","title":"Recruitment of CD55 and CD66e brush border-associated glycosylphosphatidylinositol-anchored proteins by members of the Afa/Dr diffusely adhering family of Escherichia coli that infect the human polarized intestinal Caco-2/TC7 cells.","date":"2000","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/10816511","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24740257","id":"PMC_24740257","title":"Potent and specific antitumor effect of CEA-targeted photoimmunotherapy.","date":"2014","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24740257","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8318403","id":"PMC_8318403","title":"Expression of carcinoembryonic antigen (CEA) and nonspecific crossreacting antigen (NCA) in gastrointestinal cancer; the correlation with degree of differentiation.","date":"1993","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/8318403","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31970978","id":"PMC_31970978","title":"Nanopore-based Strategy for Selective Detection of Single Carcinoembryonic Antigen (CEA) Molecules.","date":"2020","source":"Analytical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31970978","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2674159","id":"PMC_2674159","title":"Induction of polarized apical expression and vectorial release of carcinoembryonic antigen (CEA) during the process of differentiation of HT29-D4 cells.","date":"1989","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/2674159","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33046521","id":"PMC_33046521","title":"Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors.","date":"2020","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/33046521","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2537643","id":"PMC_2537643","title":"Analysis of the size of the carcinoembryonic antigen (CEA) gene family: isolation and sequencing of N-terminal domain exons.","date":"1989","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/2537643","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1572649","id":"PMC_1572649","title":"Long-range chromosomal mapping of the carcinoembryonic antigen (CEA) gene family cluster.","date":"1992","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/1572649","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11891038","id":"PMC_11891038","title":"CEA and CA 549 in serum and pleural fluid of patients with pleural effusion.","date":"2002","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/11891038","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9378556","id":"PMC_9378556","title":"Quantitative analysis of CEA expression in colorectal adenocarcinoma and serum: lack of correlation.","date":"1997","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9378556","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32993395","id":"PMC_32993395","title":"CEACAM5 stimulates the progression of non-small-cell lung cancer by promoting cell proliferation and migration.","date":"2020","source":"The Journal of international medical research","url":"https://pubmed.ncbi.nlm.nih.gov/32993395","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6751517","id":"PMC_6751517","title":"Immunohistochemical demonstration of carcinoembryonic antigen (CEA) and its correlation with grading and staging on tissue sections of urinary bladder carcinomas.","date":"1982","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/6751517","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17167768","id":"PMC_17167768","title":"GPI-anchored CEA family glycoproteins CEA and CEACAM6 mediate their biological effects through enhanced integrin alpha5beta1-fibronectin interaction.","date":"2007","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17167768","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6268270","id":"PMC_6268270","title":"A study of immunoreactive calcitonin (CT), adrenocorticotropic hormone (ACTH) and carcinoembryonic antigen (CEA) in lung cancer and other malignancies.","date":"1981","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/6268270","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11239789","id":"PMC_11239789","title":"Is there a role for CEA in innate immunity in the colon?","date":"2001","source":"Trends in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/11239789","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11300483","id":"PMC_11300483","title":"Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice.","date":"2001","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/11300483","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1383122","id":"PMC_1383122","title":"Biochemical characterization of 25 distinct carcinoembryonic antigen (CEA) epitopes recognized by 57 monoclonal antibodies and categorized into seven groups in terms of domain structure of the CEA molecule.","date":"1992","source":"Hybridoma","url":"https://pubmed.ncbi.nlm.nih.gov/1383122","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18609108","id":"PMC_18609108","title":"Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa-foeto-protein (AFP), neuron-specific enolase (NSE) and CA19.9 from the NORIP study.","date":"2008","source":"Scandinavian journal of clinical and laboratory investigation","url":"https://pubmed.ncbi.nlm.nih.gov/18609108","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11021590","id":"PMC_11021590","title":"IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice.","date":"2000","source":"Gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/11021590","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6311398","id":"PMC_6311398","title":"Immunohistochemical localization of carcinoembryonic antigen (CEA), CEA-S, and nonspecific cross-reacting antigen (NCA) in carcinomas of lung.","date":"1983","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/6311398","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29736411","id":"PMC_29736411","title":"A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis.","date":"2018","source":"NPJ breast cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29736411","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24528057","id":"PMC_24528057","title":"CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause.","date":"2014","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/24528057","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38750034","id":"PMC_38750034","title":"CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38750034","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8592083","id":"PMC_8592083","title":"Glycoproteins of the carcinoembryonic antigen (CEA) family are expressed in sweat and sebaceous glands of human fetal and adult skin.","date":"1996","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/8592083","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7459230","id":"PMC_7459230","title":"Somatic-cell hybrids producing antibodies against CEA.","date":"1981","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/7459230","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21731662","id":"PMC_21731662","title":"A novel anti-CEACAM5 monoclonal antibody, CC4, suppresses colorectal tumor growth and enhances NK cells-mediated tumor immunity.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21731662","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30321907","id":"PMC_30321907","title":"Expression of CEACAM1 or CEACAM5 in AZ-521 cells restores the type IV secretion deficiency for translocation of CagA by Helicobacter pylori.","date":"2018","source":"Cellular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/30321907","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8168994","id":"PMC_8168994","title":"CEA expression of colorectal adenocarcinomas is correlated with their resistance against LAK-cell lysis.","date":"1994","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/8168994","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20455097","id":"PMC_20455097","title":"CEA-Related CAMs.","date":"2004","source":"Handbook of experimental pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20455097","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18278069","id":"PMC_18278069","title":"The CEACAM1-mediated apoptosis pathway is activated by CEA and triggers dual cleavage of CEACAM1.","date":"2008","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/18278069","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27171273","id":"PMC_27171273","title":"Uropathogenic E. coli Exploit CEA to Promote Colonization of the Urogenital Tract Mucosa.","date":"2016","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/27171273","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10648943","id":"PMC_10648943","title":"Taking engineered anti-CEA antibodies to the clinic.","date":"1999","source":"Journal of immunological methods","url":"https://pubmed.ncbi.nlm.nih.gov/10648943","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24114705","id":"PMC_24114705","title":"Serpin B5 is a CEA-interacting biomarker for colorectal cancer.","date":"2013","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24114705","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2133556","id":"PMC_2133556","title":"Spatiotemporal expression of murine carcinoembryonic antigen (CEA) gene family members during mouse embryogenesis.","date":"1990","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/2133556","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9212243","id":"PMC_9212243","title":"Expression of transgenic carcinoembryonic antigen (CEA) in tumor-prone mice: an animal model for CEA-directed tumor immunotherapy.","date":"1997","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9212243","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8425211","id":"PMC_8425211","title":"Evaluation of human carcinoembryonic-antigen (CEA)-transduced and non-transduced murine tumors as potential targets for anti-CEA therapies.","date":"1993","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/8425211","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34740610","id":"PMC_34740610","title":"A highly-specific fully-human antibody and CAR-T cells targeting CD66e/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo.","date":"2021","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/34740610","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15003648","id":"PMC_15003648","title":"Plasmids encoding membrane-bound IL-4 or IL-12 strongly costimulate DNA vaccination against carcinoembryonic antigen (CEA).","date":"2004","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/15003648","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38760413","id":"PMC_38760413","title":"Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates.","date":"2024","source":"NPJ precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38760413","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16504122","id":"PMC_16504122","title":"Selection, affinity maturation, and characterization of a human scFv antibody against CEA protein.","date":"2006","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16504122","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29910683","id":"PMC_29910683","title":"FBW7 suppresses metastasis of colorectal cancer by inhibiting HIF1α/CEACAM5 functional axis.","date":"2018","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29910683","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15888344","id":"PMC_15888344","title":"Mouse models expressing human carcinoembryonic antigen (CEA) as a transgene: evaluation of CEA-based cancer vaccines.","date":"2005","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/15888344","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18159236","id":"PMC_18159236","title":"Colorectal hyperplasia and dysplasia due to human carcinoembryonic antigen (CEA) family member expression in transgenic mice.","date":"2007","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18159236","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24104458","id":"PMC_24104458","title":"Characterizing CEACAM5 interaction with CD8α and CD1d in intestinal homeostasis.","date":"2013","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24104458","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27038681","id":"PMC_27038681","title":"Expression of CEA, CA19-9, CA125, and EpCAM in pseudomyxoma peritonei.","date":"2016","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27038681","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24858421","id":"PMC_24858421","title":"A comprehensive phylogenetic and structural analysis of the carcinoembryonic antigen (CEA) gene family.","date":"2014","source":"Genome biology and evolution","url":"https://pubmed.ncbi.nlm.nih.gov/24858421","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12908512","id":"PMC_12908512","title":"CEA-based vaccines.","date":"2002","source":"Expert review of vaccines","url":"https://pubmed.ncbi.nlm.nih.gov/12908512","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30414968","id":"PMC_30414968","title":"An efficient constitutive expression system for Anti-CEACAM5 nanobody production in the yeast Pichia pastoris.","date":"2018","source":"Protein expression and purification","url":"https://pubmed.ncbi.nlm.nih.gov/30414968","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9001982","id":"PMC_9001982","title":"Ultrastructural localization of carcinoembryonic antigen (CEA) glycoproteins and epithelial membrane antigen (EMA) in normal and neoplastic sweat glands.","date":"1996","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/9001982","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1607061","id":"PMC_1607061","title":"Expression of CEA, CA-125 and SCC antigen by biological fluids associated with pregnancy.","date":"1992","source":"European journal of obstetrics, gynecology, and reproductive biology","url":"https://pubmed.ncbi.nlm.nih.gov/1607061","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11245984","id":"PMC_11245984","title":"The carcinoembryonic antigen (CEA) gene family in non-human primates.","date":"2001","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/11245984","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31417564","id":"PMC_31417564","title":"Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic Trimerbodies.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31417564","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30214153","id":"PMC_30214153","title":"A novel multifunctional anti-CEA-IL15 molecule displays potent antitumor activities.","date":"2018","source":"Drug design, development and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30214153","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33436840","id":"PMC_33436840","title":"Selection and characterisation of Affimers specific for CEA recognition.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33436840","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1720588","id":"PMC_1720588","title":"Keratin and carcinoembryonic antigen (CEA) in human melanoma cells.","date":"1991","source":"Virchows Archiv. B, Cell pathology including molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/1720588","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36914753","id":"PMC_36914753","title":"Identification of a CEACAM5 targeted nanobody for positron emission tomography imaging and near-infrared fluorescence imaging of colorectal cancer.","date":"2023","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/36914753","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32721480","id":"PMC_32721480","title":"NMDA receptors in the CeA and BNST differentially regulate fear conditioning to predictable and unpredictable threats.","date":"2020","source":"Neurobiology of learning and memory","url":"https://pubmed.ncbi.nlm.nih.gov/32721480","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38087365","id":"PMC_38087365","title":"Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers.","date":"2023","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38087365","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3545047","id":"PMC_3545047","title":"Carcinoembryonic antigen (CEA) expression in early embryogenesis: a study of the first trimester of gestation.","date":"1986","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/3545047","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8160902","id":"PMC_8160902","title":"Carcinoembryonic antigen (CEA) and CEA-related substances in the bile of patients with biliary diseases.","date":"1994","source":"American journal of surgery","url":"https://pubmed.ncbi.nlm.nih.gov/8160902","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10574697","id":"PMC_10574697","title":"Production of carcinoembryonic antigen (CEA) N-A3 domain in Pichia pastoris by fermentation.","date":"1999","source":"Biotechnology and applied biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10574697","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26446433","id":"PMC_26446433","title":"Serum carcinoembryonic antigen (CEA) as a clinical marker in acquired idiopathic generalized anhidrosis: a close correlation between serum CEA level and disease activity.","date":"2015","source":"Journal of the European Academy of Dermatology and Venereology : JEADV","url":"https://pubmed.ncbi.nlm.nih.gov/26446433","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12783317","id":"PMC_12783317","title":"Adenovirus-mediated prodrug-enzyme therapy for CEA-producing colorectal cancer cells.","date":"2003","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/12783317","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1212667","id":"PMC_1212667","title":"Multiple Smith-degradations of carcinoembryonic antigen (CEA) and of asialo CEA.","date":"1975","source":"Carbohydrate research","url":"https://pubmed.ncbi.nlm.nih.gov/1212667","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30248304","id":"PMC_30248304","title":"Neurotensin and dynorphin Bi-Directionally modulate CeA inhibition of oval BNST neurons in male mice.","date":"2018","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30248304","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24487967","id":"PMC_24487967","title":"Correlation between serum CEA levels and EGFR mutations in Chinese nonsmokers with lung adenocarcinoma.","date":"2014","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/24487967","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8265235","id":"PMC_8265235","title":"CEA tissue staining in colorectal cancer patients--correlation with plasma CEA, histology and staging.","date":"1993","source":"Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/8265235","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38923643","id":"PMC_38923643","title":"Hypoxia exosome derived CEACAM5 promotes tumor-associated macrophages M2 polarization to accelerate pancreatic neuroendocrine tumors metastasis via MMP9.","date":"2024","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/38923643","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10601548","id":"PMC_10601548","title":"CEA immunohistochemical localization is correlated with growth and metastasis of human gallbladder carcinoma.","date":"2000","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/10601548","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39644827","id":"PMC_39644827","title":"CEA-induced PI3K/AKT pathway activation through the binding of CEA to KRT1 contributes to oxaliplatin resistance in gastric cancer.","date":"2024","source":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/39644827","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31928422","id":"PMC_31928422","title":"The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway.","date":"2020","source":"Cancer biotherapy & radiopharmaceuticals","url":"https://pubmed.ncbi.nlm.nih.gov/31928422","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2843840","id":"PMC_2843840","title":"CEA and HMFG in hyperplastic and malignant lesions of the breast.","date":"1988","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/2843840","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34721827","id":"PMC_34721827","title":"Impact of HSP90α, CEA, NSE, SCC, and CYFRA21-1 on Lung Cancer Patients.","date":"2021","source":"Journal of healthcare engineering","url":"https://pubmed.ncbi.nlm.nih.gov/34721827","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3243976","id":"PMC_3243976","title":"Serum and salivary CEA and GICA levels in oral cavity tumours.","date":"1988","source":"The International journal of biological markers","url":"https://pubmed.ncbi.nlm.nih.gov/3243976","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32527457","id":"PMC_32527457","title":"DNA aptamers selection for carcinoembryonic antigen (CEA).","date":"2020","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/32527457","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1603061","id":"PMC_1603061","title":"Characterization of the cea gene of the ColE7 plasmid.","date":"1992","source":"Molecular & general genetics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/1603061","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38502695","id":"PMC_38502695","title":"Phenotypic screen of sixty-eight colorectal cancer cell lines identifies CEACAM6 and CEACAM5 as markers of acid resistance.","date":"2024","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/38502695","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33196697","id":"PMC_33196697","title":"Heterogeneity of CEACAM5 in breast cancer.","date":"2020","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/33196697","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34981027","id":"PMC_34981027","title":"Irisin and Carcinoembryonic Antigen (CEA) as Potential Diagnostic Biomarkers in Gastric and Colorectal Cancers.","date":"2021","source":"Reports of biochemistry & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/34981027","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3575313","id":"PMC_3575313","title":"Ultrastructural differentiation and CEA expression of butyrate-treated human pancreatic carcinoma cells.","date":"1987","source":"Pancreas","url":"https://pubmed.ncbi.nlm.nih.gov/3575313","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7101099","id":"PMC_7101099","title":"Carcinoembryonic antigen (CEA) expression in somatic cell hybrids.","date":"1982","source":"Somatic cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7101099","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12368376","id":"PMC_12368376","title":"Evaluation of a transgenic mouse model for anti-human CEA radioimmunotherapeutics.","date":"2002","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12368376","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16189514","id":"PMC_16189514","title":"Towards a proteome-scale map of the human protein-protein interaction network.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16189514","citation_count":2090,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16169070","id":"PMC_16169070","title":"A human protein-protein interaction network: a resource for annotating the proteome.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16169070","citation_count":1704,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19056867","id":"PMC_19056867","title":"Large-scale proteomics and phosphoproteomics of urinary exosomes.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19056867","citation_count":607,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8125298","id":"PMC_8125298","title":"Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.","date":"1994","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/8125298","citation_count":492,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23903773","id":"PMC_23903773","title":"Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis.","date":"2013","source":"Cancer metastasis reviews","url":"https://pubmed.ncbi.nlm.nih.gov/23903773","citation_count":430,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29121872","id":"PMC_29121872","title":"Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer.","date":"2017","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29121872","citation_count":293,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3814146","id":"PMC_3814146","title":"Primary structure of human carcinoembryonic antigen (CEA) deduced from cDNA sequence.","date":"1987","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/3814146","citation_count":277,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2803308","id":"PMC_2803308","title":"Cell adhesion activity of non-specific cross-reacting antigen (NCA) and carcinoembryonic antigen (CEA) expressed on CHO cell surface: homophilic and heterophilic adhesion.","date":"1989","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/2803308","citation_count":260,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15052268","id":"PMC_15052268","title":"Mutations in VPS33B, encoding a regulator of SNARE-dependent membrane fusion, cause arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome.","date":"2004","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15052268","citation_count":243,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27748768","id":"PMC_27748768","title":"Helicobacter pylori adhesin HopQ engages in a virulence-enhancing interaction with human CEACAMs.","date":"2016","source":"Nature microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/27748768","citation_count":216,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21988832","id":"PMC_21988832","title":"Toward an understanding of the protein interaction network of the human liver.","date":"2011","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/21988832","citation_count":207,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3670312","id":"PMC_3670312","title":"Isolation and characterization of full-length functional cDNA clones for human carcinoembryonic antigen.","date":"1987","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/3670312","citation_count":202,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10910050","id":"PMC_10910050","title":"Human carcinoembryonic antigen functions as a general inhibitor of anoikis.","date":"2000","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10910050","citation_count":192,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2342461","id":"PMC_2342461","title":"Cloning of the complete gene for carcinoembryonic antigen: analysis of its promoter indicates a region conveying cell type-specific expression.","date":"1990","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/2342461","citation_count":178,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16740002","id":"PMC_16740002","title":"Identification of N-linked glycoproteins in human saliva by glycoprotein capture and mass spectrometry.","date":"2006","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/16740002","citation_count":173,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23352032","id":"PMC_23352032","title":"Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer.","date":"2013","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/23352032","citation_count":167,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3033671","id":"PMC_3033671","title":"Isolation and characterization of cDNA clones encoding the human carcinoembryonic antigen reveal a highly conserved repeating structure.","date":"1987","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/3033671","citation_count":164,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18375392","id":"PMC_18375392","title":"Carcinoembryonic antigen and CD44 variant isoforms cooperate to mediate colon carcinoma cell adhesion to E- and L-selectin in shear flow.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18375392","citation_count":145,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27748756","id":"PMC_27748756","title":"Helicobacter pylori exploits human CEACAMs via HopQ for adherence and translocation of CagA.","date":"2016","source":"Nature microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/27748756","citation_count":145,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26207909","id":"PMC_26207909","title":"Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26207909","citation_count":143,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23533145","id":"PMC_23533145","title":"In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine.","date":"2013","source":"Proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/23533145","citation_count":138,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23322207","id":"PMC_23322207","title":"Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting.","date":"2013","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23322207","citation_count":137,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18846401","id":"PMC_18846401","title":"Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer.","date":"2008","source":"Annals of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18846401","citation_count":132,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23376485","id":"PMC_23376485","title":"Proteomic analysis of podocyte exosome-enriched fraction from normal human urine.","date":"2013","source":"Journal of proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/23376485","citation_count":126,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19386089","id":"PMC_19386089","title":"Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis.","date":"2009","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19386089","citation_count":123,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10800083","id":"PMC_10800083","title":"Molecular characterization of the surface of apoptotic neutrophils: implications for functional downregulation and recognition by phagocytes.","date":"2000","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/10800083","citation_count":121,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49988,"output_tokens":4707,"usd":0.110284},"stage2":{"model":"claude-opus-4-6","input_tokens":8250,"output_tokens":4081,"usd":0.214913},"total_usd":0.681174,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":63183,"output_tokens":6025,"usd":0.139962},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":9912,"output_tokens":3778,"usd":0.216015}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"CEACAM5 (CEA) inhibits NK cell killing via heterophilic interaction with CEACAM1 on NK cells; the N domains of both CEACAM1 and CEA are necessary but not sufficient for this interaction, and additional domains are required to regulate the balance between cis and trans interactions.\",\n      \"method\": \"Functional NK killing assays, binding assays with domain deletion constructs, Co-IP\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal binding and functional assays with domain mapping, replicated across multiple cell systems\",\n      \"pmids\": [\"15905509\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CEA and CEACAM6 co-cluster with integrin α5β1 on the cell surface and enhance binding of integrin α5β1 to fibronectin without changing surface levels, leading to increased fibronectin matrix assembly and formation of a polymerized fibronectin 'cocoon'; disrupting this with anti-fibronectin or anti-integrin α5β1 antibodies restores cellular differentiation and anoikis.\",\n      \"method\": \"Confocal microscopy co-clustering, fibronectin adhesion assays, fibronectin matrix assembly assay, monoclonal antibody blocking experiments\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (co-localization, adhesion assay, functional rescue) in a single study\",\n      \"pmids\": [\"17167768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CEA activates CEACAM1-mediated apoptosis in HT29 colon cancer cells in a manner dependent on CEACAM1 surface abundance; this pathway involves dual cleavage of CEACAM1 (intracellular and extracellular sites), caspase-1 and caspase-3 activation, and non-caspase proteases.\",\n      \"method\": \"Cell-based apoptosis assays, caspase activation assays, cleavage site mapping, gain/loss of CEACAM1 expression\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — single lab with multiple biochemical readouts; no independent replication identified\",\n      \"pmids\": [\"18278069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CEACAM5 binds CD8α (via its N domain, with glycosylation of the N domain critical for binding affinity) and interacts with CD1d through its B3 domain; CEACAM5-activated CD8+ T cells acquire suppressive activity against CD4+ T cell proliferation in vitro in the presence of IL-15 or IL-7.\",\n      \"method\": \"Purification and sequencing of mAb-reactive material, Co-IP, domain deletion analysis, glycosylation removal, T cell functional suppression assays\",\n      \"journal\": \"Mucosal immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biochemical purification, domain mapping with multiple constructs, functional validation with multiple cytokine conditions\",\n      \"pmids\": [\"24104458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"CEA is expressed exclusively at the apical surface of differentiated polarized HT29-D4 intestinal epithelial cells and is released vectorially only toward the apical side; undifferentiated cells show minimal surface CEA and low release.\",\n      \"method\": \"Independent apical/basolateral radioiodination followed by immunoprecipitation, polarized monolayer culture in permeable chambers, immunofluorescence\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct experimental localization with functional differentiation model and multiple orthogonal methods\",\n      \"pmids\": [\"2674159\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1983,\n      \"finding\": \"CEA is cleared from circulation by the liver via a hepatocyte plasma membrane receptor (hepatic binding protein) that recognizes galactosyl residues; removal of only two sialic acid residues exposes terminal galactose and dramatically accelerates hepatic uptake and lysosomal catabolism, with ~10% of CEA appearing in bile.\",\n      \"method\": \"Radiolabeled CEA biodistribution, isolated perfused liver assay, enzymatic desialylation\",\n      \"journal\": \"Digestive diseases and sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and ex vivo functional assays with receptor characterization; single lab\",\n      \"pmids\": [\"6337795\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CEACAM5 is a direct transcriptional target of HIF1α; FBW7 suppresses CEACAM5-driven migration in colorectal cancer by degrading HIF1α, thereby reducing CEACAM5 expression via its promoter.\",\n      \"method\": \"Luciferase reporter assays, chromatin immunoprecipitation (ChIP), gene expression microarray, siRNA knockdown, in vitro migration assays, immunohistochemistry on tissue microarray\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and luciferase establish direct transcriptional regulation; functional validation by knockdown migration assays\",\n      \"pmids\": [\"29910683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CEACAM5 or CEACAM1 expression (but not CEACAM6) in AZ-521 cells restores H. pylori type IV secretion system (T4SS) competency for CagA injection and phosphorylation, identifying CEACAM5 as a receptor for T4SS-dependent CagA delivery; CEACAM expression was also accompanied by tyrosine dephosphorylation of vinculin and cortactin.\",\n      \"method\": \"Genetic complementation (overexpression of CEACAM family members in AZ-521 cells), CagA phosphorylation assay, immunoblot\",\n      \"journal\": \"Cellular microbiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic complementation with direct functional readout; specificity established by testing multiple family members\",\n      \"pmids\": [\"30321907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CEACAM5 engagement by bacterial CEACAM-binding adhesins (neisserial Opa proteins or Afa/Dr adhesins) suppresses epithelial exfoliation, increases integrin activity, and promotes matrix adhesion in vitro; in CEA-transgenic mice, this translates to improved uropathogenic E. coli colonization of the urogenital tract compared to wildtype mice.\",\n      \"method\": \"Heterologous expression of Opa proteins in non-pathogenic E. coli, in vitro adhesion/exfoliation assays, in vivo colonization in CEA-transgenic vs. wildtype mice\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro mechanistic assays combined with in vivo genetic model; multiple bacterial adhesin systems tested\",\n      \"pmids\": [\"27171273\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Afa/Dr DAEC strains use CEACAM5 (CD66e) as a receptor on polarized intestinal Caco-2/TC7 cells; infection causes clustering of CEACAM5 around adhering bacteria, and anti-CEACAM5 antibodies inhibit bacterial adhesion.\",\n      \"method\": \"Infection assays, anti-CD66e antibody inhibition, stable transfection of HeLa cells with CD66e, immunofluorescence clustering assays, DraE structural mutant analysis\",\n      \"journal\": \"Infection and immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor function confirmed by antibody blocking, ectopic expression in non-permissive cells, and structural mutant analysis\",\n      \"pmids\": [\"10816511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Antibodies targeting the NH2-terminal (MN-3) and A1B1 (MN-15) domains shared by CEACAM5 and CEACAM6 inhibit tumor cell migration and invasion through extracellular matrix; all three anti-CEACAM5/6 antibody Fabs decrease tumor cell adhesion to endothelial cells, and MN-15 Fab reduces adhesion to fibronectin specifically; in vivo, MN-3 and MN-15 Fabs have antimetastatic effects.\",\n      \"method\": \"In vitro migration, invasion (ECM penetration), and adhesion assays with multiple cell lines; in vivo micrometastasis model\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional in vitro assays with multiple cell lines and in vivo validation; single lab\",\n      \"pmids\": [\"16204051\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CEACAM5 overexpression enriches for an epithelial gene expression pattern and promotes mesenchymal-to-epithelial transition (MET), driving tumor outgrowth at metastatic sites; elevated CEACAM5 in lung metastases inversely correlates with the mesenchymal marker vimentin in patient tissues.\",\n      \"method\": \"In vivo gain-of-function screen (serial passaging of lung metastases, transcriptomic signature, high-throughput overexpression screen in xenograft), patient tissue analysis\",\n      \"journal\": \"NPJ breast cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo functional screen with transcriptomic validation and patient tissue correlation; single lab\",\n      \"pmids\": [\"29736411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Serpin B5 specifically interacts and co-localizes with CEACAM5 (CEA) in colorectal cancer cells; serpin B5 levels are positively correlated with CEA levels in cancer cell lines, and serpin B5 expression was downregulated when CEA was suppressed.\",\n      \"method\": \"2D gel electrophoresis, MALDI-MS, co-immunoprecipitation, confocal microscopy co-localization, Western blot, ELISA\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP and co-localization confirm interaction; mechanistic downstream function not fully resolved\",\n      \"pmids\": [\"24114705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"In CEA/CEACAM6 transgenic mice, progressive increases in colonocyte CEA/CEACAM6 expression lead to increased integrin α5 surface levels and AKT activation, inhibition of differentiation and anoikis, increased crypt proliferation and fission, and development of hyperplasia, dysplasia and serrated adenomatous colonic morphology.\",\n      \"method\": \"Transgenic mouse model with graded CEA/CEACAM6 expression, colonocyte surface marker analysis, AKT phosphorylation assay, histology\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic model with dose-response and multiple molecular readouts\",\n      \"pmids\": [\"18159236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Differential glycosylation of CEACAM5 in colorectal tumor tissue compared to normal mucosa includes high levels of Lewis X and Lewis Y blood group carbohydrates and branched N-glycans, enabling interaction with the human C-type lectin DC-SIGN on antigen-presenting cells; increased mannose expression correlates with Galectin-3 binding.\",\n      \"method\": \"Lectin-capture ELISA with plant lectins and human C-type lectins on patient-matched normal and tumor tissue extracts\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — binding assay panel demonstrates glycan-dependent interactions; functional consequences inferred but not directly tested\",\n      \"pmids\": [\"21823122\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CEACAM5, secreted in exosomes from hypoxic pancreatic neuroendocrine tumor (pNET) cells, induces M2 polarization of tumor-associated macrophages through activation of the MAPK signaling pathway; M2-polarized TAMs in turn facilitate migration and invasion of pNET cells.\",\n      \"method\": \"Exosome isolation and co-culture experiments, MAPK pathway inhibition, macrophage polarization assays, migration/invasion assays\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — functional co-culture with pathway inhibition; single lab, no independent replication\",\n      \"pmids\": [\"38923643\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CEA binds to keratin 1 (KRT1) on the cell surface, activating the PI3K/AKT signaling pathway, which confers oxaliplatin resistance in gastric cancer cells; the small molecule inhibitor evacetrapib competitively inhibits the CEA-KRT1 interaction and restores oxaliplatin sensitivity.\",\n      \"method\": \"Proteomic analysis, Co-IP, GST pull-down, immunofluorescence co-localization, PI3K/AKT pathway readout, IC50 assays, organoid culture, xenograft models, virtual screening, surface plasmon resonance\",\n      \"journal\": \"Drug resistance updates\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — interaction confirmed by multiple biochemical methods (Co-IP, GST pull-down, SPR), functional pathway activation validated in vitro and in vivo, with small molecule rescue\",\n      \"pmids\": [\"39644827\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CEACAM5 depletion in NSCLC cells inhibits proliferation and migration by activating p38-Smad2/3 signaling, and CEACAM5 knockdown suppresses tumor growth in vivo.\",\n      \"method\": \"siRNA knockdown, MTT/colony formation assays, wound healing assay, immunoblot for p38-Smad2/3 signaling, mouse xenograft\",\n      \"journal\": \"The Journal of international medical research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — loss-of-function with defined signaling pathway readout; single lab, mechanistic details limited\",\n      \"pmids\": [\"32993395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ASCL1 (a pioneer transcription factor) drives neuroendocrine reprogramming of prostate cancer associated with increased chromatin accessibility at the CEACAM5 core promoter and consequent CEACAM5 expression, revealing epigenetic regulation of CEACAM5 transcription.\",\n      \"method\": \"Neuroendocrine transdifferentiation assay, ASCL1 overexpression, ATAC-seq/chromatin accessibility analysis of CEACAM5 promoter\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — chromatin accessibility assay + functional transdifferentiation model; single lab\",\n      \"pmids\": [\"33199493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"CEA expression on colorectal carcinoma cells correlates with resistance to LAK cell lysis; CEA-expressing spheroids prevent LAK cell infiltration, and LAK cell adhesion to CEA-expressing monolayers is minimal, indicating CEA functions as an immune escape mechanism.\",\n      \"method\": \"LAK cell adherence, infiltration, and cytotoxicity assays against tumor spheroids/monolayers; correlation with CEA secretion levels\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — functional correlation across 20 cell lines with multiple assay modalities; mechanism not fully dissected\",\n      \"pmids\": [\"8168994\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CEACAM5 is a GPI-anchored glycoprotein that functions as an intercellular adhesion molecule and immune modulator: it inhibits NK cell killing by engaging CEACAM1 on NK cells through heterophilic N-domain interactions; promotes tumor metastasis by co-clustering with integrin α5β1 to enhance fibronectin binding and matrix assembly; is transcriptionally regulated by HIF1α (and suppressed via FBW7-mediated HIF1α degradation) as well as by ASCL1-driven chromatin remodeling; serves as a receptor for bacterial pathogens (H. pylori T4SS CagA delivery, Afa/Dr DAEC adhesins); interacts with CD8α and CD1d on intestinal epithelial cells to activate regulatory CD8+ T cells; binds KRT1 to activate PI3K/AKT signaling and confer chemotherapy resistance; undergoes tumor-associated glycan changes (Lewis X/Y, branched N-glycans) that enable DC-SIGN recognition; and is trafficked to the apical membrane of polarized epithelial cells with vectorial apical release regulated by differentiation state.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1987,\n      \"finding\": \"The primary structure of CEACAM5 (CEA) was determined from cDNA cloning, revealing it is synthesized as a precursor with a signal peptide followed by 668 amino acids comprising an N-terminal domain, three highly homologous repeated domains of 178 amino acids each (containing four conserved cysteines and multiple N-glycosylation sites per repeat), and a C-terminal hydrophobic membrane-anchoring domain, establishing CEA as a member of the immunoglobulin superfamily.\",\n      \"method\": \"cDNA cloning and sequencing, in vitro transcription/translation, cell transfection with immunoprecipitation\",\n      \"journal\": \"Biochemical and biophysical research communications / Molecular and cellular biology / PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — independently replicated across three labs in the same year using full-length cDNA cloning and sequencing\",\n      \"pmids\": [\"3814146\", \"3670312\", \"3033671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"CEACAM5 (CEA) and NCA expressed on CHO cell surfaces function as calcium-independent cell adhesion molecules through both homophilic (CEA-CEA) and heterophilic (CEA-NCA) interactions; CEA-CEA homophilic adhesion was the strongest, and all interactions were completely blocked by anti-CEA Fab' fragments.\",\n      \"method\": \"CHO cell transfection with CEA/NCA cDNAs, cell aggregation assay, 51Cr-labeled cell adhesion assay with antibody inhibition\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct functional adhesion assay with genetic expression system and antibody blockade controls\",\n      \"pmids\": [\"2803308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"During differentiation of HT29-D4 colon cancer cells, CEA expression becomes restricted exclusively to the apical cell surface of polarized epithelial monolayers, and CEA release is vectorially directed toward the apical compartment; undifferentiated cells express and release only small amounts of CEA.\",\n      \"method\": \"Independent radioiodination of apical vs. basolateral domains of polarized monolayers followed by immunoprecipitation; permeable chamber culture assays\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct domain-specific labeling experiment with functional polarization readout\",\n      \"pmids\": [\"2674159\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"The CEA gene promoter region (~400 nucleotides upstream of the translational start) contains cis-acting sequences sufficient for cell-type-specific expression, showing ~9-fold higher activity in CEA-producing adenocarcinoma cells (SW403) than in non-producing HeLa cells; the promoter lacks classic TATA or CAAT boxes.\",\n      \"method\": \"Promoter-indicator gene transfection assays in CEA-producing vs. non-producing cell lines\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct promoter functional assay with cell-type specificity control\",\n      \"pmids\": [\"2342461\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1983,\n      \"finding\": \"CEA clearance from circulation is mediated by the liver: removal of as few as two sialic acid residues exposes terminal galactosyl residues recognized by a hepatocyte plasma membrane receptor (hepatic binding protein), leading to rapid uptake and lysosomal catabolism; ~70% of intact 125I-CEA is cleared by the liver within 1 hour, and ~10% appears in bile.\",\n      \"method\": \"Isolated perfused liver experiments, 125I-labeled CEA biodistribution, enzymatic desialylation\",\n      \"journal\": \"Digestive diseases and sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct biochemical experiment with isotope tracing and enzymatic manipulation\",\n      \"pmids\": [\"6337795\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CEACAM5 (CEA) and CEACAM6 function as general inhibitors of anoikis (apoptosis triggered by loss of extracellular matrix anchorage) when overexpressed in multiple cell types; CEACAM1, by contrast, does not inhibit anoikis, identifying a specific anti-apoptotic function unique to GPI-anchored CEA family members.\",\n      \"method\": \"Stable overexpression of CEA/CEACAM6/CEACAM1 in multiple cell lines, anoikis assays in suspension culture\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple cell systems tested with appropriate family-member controls\",\n      \"pmids\": [\"10910050\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CEACAM5 on tumor cells interacts heterophilically with CEACAM1 on NK cells, and this heterophilic interaction inhibits NK cell-mediated cytotoxicity against tumor cells; the N-terminal domains of both CEACAM1 and CEA are necessary but not sufficient for this interaction, and additional domains are required to regulate cis vs. trans interactions.\",\n      \"method\": \"Functional NK killing assays, binding assays with domain mutants, co-incubation experiments\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal binding and functional assays with domain dissection\",\n      \"pmids\": [\"15905509\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CEACAM5 (CEA) and CEACAM6 co-cluster with integrin α5β1 on the cell surface, enhance integrin α5β1 binding to fibronectin without altering surface integrin levels, promote fibronectin matrix assembly forming a polymerized fibronectin 'cocoon' around cells, and thereby inhibit cellular differentiation and anoikis; disruption with anti-fibronectin or anti-integrin α5β1 antibodies restores differentiation and anoikis.\",\n      \"method\": \"Confocal microscopy, specific antibody co-clustering experiments, fibronectin binding and matrix assembly assays, differentiation/anoikis rescue experiments\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods with functional rescue experiments\",\n      \"pmids\": [\"17167768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CEA (CEACAM5) functions as an E-selectin and L-selectin ligand on colon carcinoma cells, carrying sialofucosylated glycans that support rolling adhesion under flow conditions; CEA and CD44 variant isoforms cooperate to mediate tumor cell adhesion to E- and L-selectin at elevated shear stresses, providing a potential mechanism for hematogenous metastasis.\",\n      \"method\": \"Immunoaffinity chromatography, tandem mass spectrometry identification, bead-coating with purified CEA, blot rolling and flow-based adhesion assays, stable CD44 knockdown cell lines\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — biochemical purification, MS identification, reconstituted adhesion assay under flow, genetic knockdown\",\n      \"pmids\": [\"18375392\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CEA (CEACAM5) acts as an inducer of CEACAM1-mediated apoptosis in HT29 colon cancer cells, an effect dependent on CEACAM1 cell-surface abundance; CEACAM1-mediated apoptosis triggered by CEA involves dual cleavage of CEACAM1 (at both intracellular and extracellular sites), caspase-1 and caspase-3 activation, and non-caspase proteases.\",\n      \"method\": \"CEA treatment of HT29 cells, CEACAM1 cleavage analysis, caspase activation assays, HEK293/Jurkat cell models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple mechanistic readouts in single study; single lab\",\n      \"pmids\": [\"18278069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CEACAM5 (identified as the epithelial glycoprotein gp180) binds CD8α through its N-terminal domain in a glycosylation-dependent manner, activates CD8-associated Lck kinase, and is the only CEACAM family member that interacts with CD1d through its B3 domain; CEACAM5-activated CD8+ T cells acquire suppressor activity against CD4+ T cell proliferation in vitro in the presence of IL-15 or IL-7.\",\n      \"method\": \"Protein purification and sequence analysis, binding assays with domain deletion mutants, Lck activation assays, T-cell suppression assays, confocal co-localization\",\n      \"journal\": \"Mucosal immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple binding and functional assays; single lab\",\n      \"pmids\": [\"24104458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"H. pylori outer membrane protein HopQ binds the N-terminal IgV-like domain of CEACAM5 (and CEACAM1, 3, 6) in a glycan-independent manner with high affinity (KD 23–268 nM), and this HopQ-CEACAM interaction is required for translocation of the virulence factor CagA into host cells via the cag type IV secretion system and enhances IL-8 release; a β-hairpin insertion domain (HopQ-ID) in HopQ mediates CEACAM binding.\",\n      \"method\": \"Crystal structure of HopQ, KD measurements, genetic introduction of CEACAM constructs into AZ-521 cells, CagA phosphorylation assays, IL-8 release assays, competitive peptide inhibition\",\n      \"journal\": \"Nature microbiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus functional validation in multiple complementary assays, independently replicated in two concurrent papers\",\n      \"pmids\": [\"27748768\", \"27748756\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Expression of CEACAM1 or CEACAM5 (but not CEACAM6) in CEACAM-deficient AZ-521 cells is sufficient to restore H. pylori T4SS-mediated CagA injection and phosphorylation, and is accompanied by tyrosine dephosphorylation of cytoskeletal proteins vinculin and cortactin; the T4SS delivery pathway requires both integrin-β1 and CEACAM1/CEACAM5.\",\n      \"method\": \"Genetic complementation of CEACAM-deficient cells, CagA phosphorylation assays, immunoblotting for vinculin/cortactin dephosphorylation\",\n      \"journal\": \"Cellular microbiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic complementation with specific molecular readouts; single lab\",\n      \"pmids\": [\"30321907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Bacterial engagement of CEA (CEACAM5) by neisserial Opa proteins or uropathogenic E. coli Afa/Dr adhesins alters gene expression, increases integrin activity, promotes matrix adhesion of cervical and vaginal epithelial cells, and suppresses exfoliation to promote urogenital tract colonization; these CEA-triggered events were demonstrated to be sufficient for colonization suppression using CEA-transgenic vs. wildtype mouse in vivo comparison.\",\n      \"method\": \"Heterologous Opa expression in non-pathogenic E. coli, in vitro gene expression and integrin activity assays, CEA-transgenic mouse colonization model vs. wildtype, CEACAM-binding adhesin deletion mutants\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal in vitro and in vivo methods with genetic controls\",\n      \"pmids\": [\"27171273\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CEACAM5 is a direct transcriptional target of HIF1α, and FBW7 suppresses CEACAM5 expression and colorectal cancer cell migration through a HIF1α-dependent mechanism; ChIP and luciferase assays demonstrated HIF1α binding to the CEACAM5 promoter, and FBW7 regulates HIF1α protein levels to control CEACAM5 expression.\",\n      \"method\": \"Luciferase reporter assay, chromatin immunoprecipitation (ChIP), loss-of-function and gain-of-function experiments, in vitro migration assays, gene expression microarray\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and luciferase assays with functional validation; single lab\",\n      \"pmids\": [\"29910683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CEACAM5 overexpression drives metastatic colonization by promoting mesenchymal-to-epithelial transition (MET), enriching for an epithelial gene expression pattern, and facilitating tumor outgrowth at metastatic sites; an inverse correlation between CEACAM5 and the mesenchymal marker vimentin was demonstrated in patient lung metastases.\",\n      \"method\": \"In vivo serial passaging of lung metastases, high-throughput gain-of-function screen in vivo, gene expression analysis, patient tissue validation\",\n      \"journal\": \"NPJ breast cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo functional screen with molecular mechanism (MET promotion); single lab\",\n      \"pmids\": [\"29736411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CEACAM5 expression in neuroendocrine prostate cancer (NEPC) is driven by the pioneer transcription factor ASCL1, which promotes neuroendocrine reprogramming associated with increased chromatin accessibility at the CEACAM5 core promoter; CEACAM5 depletion or antibody-drug conjugate (labetuzumab govitecan) treatment induces DNA damage and antitumor responses in CEACAM5+ models.\",\n      \"method\": \"Neuroendocrine transdifferentiation assay, chromatin accessibility analysis (ATAC-seq), patient-derived xenograft models, multiplex immunofluorescence\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epigenomic and functional validation of ASCL1-driven CEACAM5 regulation; single lab\",\n      \"pmids\": [\"33199493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CEACAM5 depletion in NSCLC cells inhibits proliferation and migration by activating p38-Smad2/3 signaling, and CEACAM5 suppresses this pathway to promote tumor progression in vitro and in vivo.\",\n      \"method\": \"siRNA knockdown, MTT assay, wound healing assay, immunoblotting for p38-Smad2/3 pathway, xenograft mouse model\",\n      \"journal\": \"The Journal of international medical research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, single knockdown approach with pathway western blots but no rescue or epistasis confirmation\",\n      \"pmids\": [\"32993395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In colorectal cancer tissue, CEACAM5 (CEA) carries distinct tumor-associated carbohydrate modifications compared to normal tissue, including high levels of Lewis X and Lewis Y blood-group antigens that enable recognition and binding by the human C-type lectin DC-SIGN on antigen-presenting cells; increased mannose and branched N-glycans correlate with Galectin-3 binding.\",\n      \"method\": \"CEA/MUC1 capture ELISA with plant and human C-type lectins, 48-patient matched normal/tumor comparison\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic comparative glycan profiling with multiple lectins on matched patient samples\",\n      \"pmids\": [\"21823122\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CEA (CEACAM5) activates the PI3K/AKT pathway by directly binding to KRT1 (keratin 1) at the cell surface, and this CEA-KRT1 interaction promotes oxaliplatin resistance in gastric cancer cells; the interaction was confirmed by Co-IP, GST pull-down, and immunofluorescence colocalization, and a small molecule inhibitor (evacetrapib) competitively inhibits this interaction to restore drug sensitivity.\",\n      \"method\": \"Co-immunoprecipitation, GST pull-down, immunofluorescence colocalization, proteomic analysis, virtual screening and surface plasmon resonance for inhibitor validation, CCK8/colony formation/xenograft assays, organoid model\",\n      \"journal\": \"Drug resistance updates\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal binding assays (Co-IP, GST pulldown) with functional validation; single lab\",\n      \"pmids\": [\"39644827\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Under hypoxia, pNET cells package CEACAM5 into exosomes; exosomal CEACAM5 induces M2 polarization of tumor-associated macrophages (TAM) through activation of the MAPK signaling pathway, and M2-polarized TAM in turn enhance pNET cell migration and invasion.\",\n      \"method\": \"Exosome isolation and characterization, co-culture experiments, MAPK pathway inhibition, macrophage polarization assays, in vitro migration/invasion assays\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — mechanistic pathway identified but single lab, no genetic rescue confirming CEACAM5 specificity in exosomes\",\n      \"pmids\": [\"38923643\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Antibody Fabs targeting the N-terminal (MN-3) or A1B1 (MN-15) domains shared by CEACAM5 and CEACAM6 inhibit tumor cell migration, invasion through extracellular matrix, and adhesion to endothelial cells; MN-15 Fab also reduced adhesion to fibronectin in some cell lines; MN-3 and MN-15 Fabs showed antimetastatic effects in vivo in a human colonic micrometastasis model.\",\n      \"method\": \"Migration assay, Matrigel invasion assay, tumor-endothelial cell adhesion assay, fibronectin/vitronectin/laminin/collagen adhesion assays, in vivo mouse metastasis model\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple in vitro adhesion/invasion assays plus in vivo validation; single lab\",\n      \"pmids\": [\"16204051\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Serpin B5 (maspin) physically interacts with CEA (CEACAM5) in colorectal cancer cells; this interaction was identified by 2D-gel proteomics of CEA-suppressed cells, confirmed by co-immunoprecipitation and confocal colocalization, and serpin B5 protein levels positively correlate with CEA levels in colon cancer cell lines and patient blood.\",\n      \"method\": \"Two-dimensional gel electrophoresis, MALDI-MS, co-immunoprecipitation, confocal microscopy colocalization, western blot, ELISA\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — Co-IP and colocalization confirmed, but functional consequence of CEA-serpin B5 interaction not fully mechanistically resolved\",\n      \"pmids\": [\"24114705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"In CEA/CEACAM6 transgenic mice expressing these molecules at levels found in human colorectal carcinomas, colonocyte surface integrin α5 levels and AKT activation progressively increase with CEA/CEACAM6 expression, and colons show progressive hyperplasia, increased crypt fission, inhibition of differentiation and anoikis/apoptosis, culminating in a continuous mosaic of severe hyperplasia, dysplasia and serrated adenomatous morphology.\",\n      \"method\": \"Human CEA/CEACAM6 genomic transgenic mouse model with titrated expression, histology, immunostaining for integrin α5 and phospho-AKT\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic model with molecular pathway measurements; single lab\",\n      \"pmids\": [\"18159236\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CEACAM5 (CEA) is a GPI-anchored immunoglobulin superfamily glycoprotein that functions as a homophilic and heterophilic cell adhesion molecule; it inhibits anoikis by enhancing integrin α5β1–fibronectin interaction and fibronectin matrix assembly, evades NK-mediated immune surveillance through heterophilic interaction with inhibitory CEACAM1 on NK cells, promotes metastasis partly by acting as an E/L-selectin ligand and by driving mesenchymal-to-epithelial transition, activates CD8+ suppressor T cells via CD8α and CD1d binding, serves as a receptor for bacterial pathogens (H. pylori HopQ, Afa/Dr adhesins) enabling CagA translocation and suppression of epithelial exfoliation, is transcriptionally regulated by HIF1α and ASCL1 via chromatin remodeling at its promoter, and can activate PI3K/AKT signaling through direct binding to KRT1, promoting drug resistance.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CEACAM5 is a GPI-anchored cell-surface glycoprotein that functions as an intercellular adhesion molecule, pathogen receptor, and immune modulator in epithelial tissues. It inhibits NK cell and LAK cell cytotoxicity by engaging CEACAM1 through heterophilic N-domain interactions, and activates regulatory CD8+ T cells by binding CD8α (via its glycosylated N domain) and CD1d (via its B3 domain) on intestinal epithelial cells [PMID:15905509, PMID:8168994, PMID:24104458]. CEACAM5 co-clusters with integrin α5β1 to enhance fibronectin binding and matrix assembly, activates AKT signaling, suppresses anoikis and differentiation in colonic epithelium, and promotes mesenchymal-to-epithelial transition at metastatic sites; it also binds KRT1 to activate PI3K/AKT signaling and confer chemotherapy resistance [PMID:17167768, PMID:18159236, PMID:29736411, PMID:39644827]. CEACAM5 serves as a receptor for bacterial pathogens including Afa/Dr DAEC adhesins and H. pylori T4SS-mediated CagA delivery, and its transcription is directly regulated by HIF1α and ASCL1-driven chromatin remodeling [PMID:10816511, PMID:30321907, PMID:29910683, PMID:33199493].\",\n  \"teleology\": [\n    {\n      \"year\": 1983,\n      \"claim\": \"Establishing how circulating CEACAM5 is cleared resolved its metabolic fate: hepatocyte galactose-recognizing receptors mediate rapid uptake once sialic acid residues are removed, channeling CEACAM5 to lysosomal degradation and bile excretion.\",\n      \"evidence\": \"Radiolabeled CEA biodistribution and isolated perfused liver assay with enzymatic desialylation\",\n      \"pmids\": [\"6337795\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the hepatic galactose-binding receptor not molecularly defined\", \"In vivo half-life kinetics in humans not established\"]\n    },\n    {\n      \"year\": 1989,\n      \"claim\": \"Demonstrating that CEACAM5 is exclusively apical and vectorially released in polarized epithelial cells established its role as a differentiation-regulated luminal marker, setting the framework for understanding its accessibility to pathogens and immune cells.\",\n      \"evidence\": \"Independent apical/basolateral radioiodination, immunoprecipitation, and immunofluorescence in polarized HT29-D4 monolayers\",\n      \"pmids\": [\"2674159\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"GPI-anchor sorting signals not dissected\", \"Mechanism of differentiation-coupled upregulation not identified\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Correlating CEACAM5 expression with resistance to LAK cell lysis and impaired immune cell infiltration into tumor spheroids provided the first evidence that CEACAM5 functions as an immune escape molecule in cancer.\",\n      \"evidence\": \"LAK cell cytotoxicity, adhesion, and spheroid infiltration assays across 20 colorectal carcinoma cell lines\",\n      \"pmids\": [\"8168994\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism not fully dissected — correlative across cell lines\", \"Receptor on LAK cells mediating inhibition not identified in this study\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identifying CEACAM5 as the receptor for Afa/Dr DAEC adhesins on intestinal epithelial cells established a direct pathogen-receptor function, with antibody blocking and ectopic expression confirming necessity and sufficiency.\",\n      \"evidence\": \"Infection assays with anti-CEACAM5 antibody inhibition, HeLa transfection with CD66e, DraE structural mutant analysis on polarized Caco-2/TC7 cells\",\n      \"pmids\": [\"10816511\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of DraE–CEACAM5 interaction not resolved\", \"Whether CEACAM5 is the sole receptor for all Afa/Dr strains unclear\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Mapping the heterophilic CEACAM5–CEACAM1 interaction to their N domains and showing it inhibits NK cell killing resolved the molecular basis of the immune evasion phenotype first observed in 1994, revealing that additional domains regulate cis/trans binding balance.\",\n      \"evidence\": \"NK killing assays, domain deletion constructs, Co-IP across multiple cell systems\",\n      \"pmids\": [\"15905509\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural details of multidomain regulation of cis vs. trans binding unknown\", \"In vivo relevance in tumor immune evasion not directly tested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrating that antibodies targeting CEACAM5/6 N-terminal and A1B1 domains inhibit tumor cell migration, invasion, and endothelial adhesion established these domains as functional mediators of metastatic behavior.\",\n      \"evidence\": \"In vitro migration/invasion/adhesion assays with multiple cell lines; in vivo micrometastasis model with Fab fragments\",\n      \"pmids\": [\"16204051\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding partners on endothelial cells not identified\", \"Single lab without independent replication\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showing that CEACAM5 co-clusters with integrin α5β1 to enhance fibronectin binding and matrix assembly — and that disrupting this restores anoikis — connected CEACAM5 to integrin-mediated survival signaling and provided a mechanistic link to metastasis.\",\n      \"evidence\": \"Confocal co-clustering, fibronectin adhesion and matrix assembly assays, antibody blocking/functional rescue in vitro; transgenic mouse model showing dose-dependent AKT activation, hyperplasia, and dysplasia\",\n      \"pmids\": [\"17167768\", \"18159236\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct physical interaction between CEACAM5 and integrin α5β1 not demonstrated by biochemical pull-down\", \"Whether GPI-anchor raft co-localization is necessary for co-clustering unclear\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Revealing that CEACAM5 activates CEACAM1-mediated apoptosis through dual cleavage events and caspase-1/3 activation showed CEACAM5 can trigger cell death via CEACAM1, not only inhibit killing — adding context-dependence to the CEACAM5–CEACAM1 axis.\",\n      \"evidence\": \"Apoptosis assays, caspase activation, cleavage site mapping in HT29 colon cancer cells with modulated CEACAM1 expression\",\n      \"pmids\": [\"18278069\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No independent replication; single cell line\", \"Proteases responsible for extracellular cleavage not identified\", \"Conditions that tip the balance between immune evasion and apoptosis induction unresolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Characterizing tumor-specific glycosylation changes on CEACAM5 (Lewis X/Y, branched N-glycans) that enable DC-SIGN recognition on antigen-presenting cells revealed a glycan-dependent mechanism for immune cell engagement beyond the CEACAM1 axis.\",\n      \"evidence\": \"Lectin-capture ELISA with plant lectins and human C-type lectins on patient-matched normal and tumor tissue extracts\",\n      \"pmids\": [\"21823122\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequences of DC-SIGN engagement not directly tested\", \"Glycan structures not resolved at site-specific level\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Mapping CEACAM5 binding to CD8α (N domain, glycosylation-dependent) and CD1d (B3 domain) and showing this activates suppressive CD8+ T cells established CEACAM5 as a regulator of mucosal immune tolerance through a non-classical T cell pathway.\",\n      \"evidence\": \"Purification, Co-IP, domain deletion analysis, glycosylation removal, T cell suppression assays with IL-15/IL-7\",\n      \"pmids\": [\"24104458\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of CEACAM5-activated regulatory CD8+ T cells not demonstrated\", \"Whether tumor CEACAM5 exploits this pathway for immune evasion not tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identifying CEACAM5 as a receptor for H. pylori T4SS-mediated CagA delivery expanded its pathogen receptor role beyond Afa/Dr adhesins, and showing that bacterial CEACAM-binding adhesins suppress epithelial exfoliation and enhance integrin activity linked pathogen exploitation to CEACAM5's integrin-modulating function.\",\n      \"evidence\": \"Genetic complementation with CEACAM family members in AZ-521 cells for CagA injection; in vivo colonization in CEA-transgenic vs. wildtype mice for UPEC\",\n      \"pmids\": [\"30321907\", \"27171273\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of T4SS interaction with CEACAM5 unknown\", \"Whether integrin activation by CEACAM5 is required for enhanced colonization not directly tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrating that HIF1α directly binds the CEACAM5 promoter and drives its transcription — and that FBW7-mediated HIF1α degradation suppresses CEACAM5-driven migration — established hypoxia-responsive transcriptional regulation of CEACAM5 in colorectal cancer.\",\n      \"evidence\": \"ChIP, luciferase reporter, siRNA knockdown, migration assays, tissue microarray immunohistochemistry\",\n      \"pmids\": [\"29910683\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether HIF1α regulation operates in non-tumor tissues unknown\", \"Contribution relative to other transcription factors not quantified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showing that CEACAM5 overexpression drives mesenchymal-to-epithelial transition and tumor outgrowth at metastatic sites resolved a longstanding paradox — that an epithelial adhesion molecule promotes metastasis — by linking it to MET at secondary sites.\",\n      \"evidence\": \"In vivo gain-of-function screen with serial passaging of lung metastases, transcriptomic signature, xenograft, patient tissue analysis\",\n      \"pmids\": [\"29736411\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signaling pathway downstream of CEACAM5 driving MET not identified\", \"Single lab, breast cancer context — generalizability unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identifying ASCL1-driven chromatin remodeling at the CEACAM5 promoter during neuroendocrine transdifferentiation revealed an epigenetic axis of transcriptional regulation distinct from HIF1α, linking CEACAM5 expression to lineage plasticity.\",\n      \"evidence\": \"ASCL1 overexpression, ATAC-seq chromatin accessibility analysis, neuroendocrine transdifferentiation assay in prostate cancer cells\",\n      \"pmids\": [\"33199493\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ASCL1 directly binds CEACAM5 promoter or acts indirectly not resolved\", \"Single lab; no CEACAM5 functional assays performed\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Discovering that CEACAM5 binds KRT1 on the cell surface to activate PI3K/AKT and confer oxaliplatin resistance — reversible by the small molecule evacetrapib — identified a druggable signaling axis and a new mechanism of chemoresistance.\",\n      \"evidence\": \"Co-IP, GST pull-down, SPR, PI3K/AKT readouts, organoid culture, xenograft, virtual screening\",\n      \"pmids\": [\"39644827\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"KRT1 is unconventional as a surface receptor — mechanism of its surface presentation unclear\", \"Generalizability beyond gastric cancer not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrating that exosomal CEACAM5 from hypoxic tumor cells induces M2 macrophage polarization via MAPK signaling revealed a paracrine immunomodulatory function beyond direct cell-contact mechanisms.\",\n      \"evidence\": \"Exosome isolation and co-culture, MAPK pathway inhibition, macrophage polarization and migration/invasion assays in pancreatic neuroendocrine tumor model\",\n      \"pmids\": [\"38923643\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether exosomal CEACAM5 engages CEACAM1 or another receptor on macrophages not determined\", \"Single lab, single tumor type\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis of CEACAM5's multidomain regulation of cis versus trans CEACAM1 binding, the identity of the receptor mediating exosomal CEACAM5 uptake on macrophages, and the mechanism by which GPI-anchored CEACAM5 transduces intracellular signals through integrin co-clustering and KRT1 binding remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution structure of full-length CEACAM5 or CEACAM5–CEACAM1 complex\", \"Signal transduction mechanism from a GPI-anchored protein lacking an intracellular domain not mechanistically explained\", \"In vivo validation of CEACAM5-mediated regulatory T cell activation in tumor immune evasion lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [1, 8, 9, 10]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 3, 19]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [7, 9, 16]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [4, 1, 9]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [4, 5, 15]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 3, 14, 15, 19]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [13, 16, 17]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [1, 8, 10]},\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [1, 13]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [11, 16, 17]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CEACAM1\",\n      \"ITGA5\",\n      \"KRT1\",\n      \"CD8A\",\n      \"CD1D\",\n      \"SERPINB5\",\n      \"CEACAM6\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"CEACAM5 is a GPI-anchored immunoglobulin superfamily glycoprotein that mediates calcium-independent homophilic and heterophilic cell adhesion—including interactions with CEACAM1 and CEACAM6—and is expressed on the apical surface of polarized epithelial cells [PMID:2803308, PMID:2674159]. It inhibits anoikis by co-clustering with integrin α5β1 to enhance fibronectin binding and matrix assembly, activates PI3K/AKT signaling in part through direct interaction with KRT1, and promotes metastatic colonization by functioning as an E/L-selectin ligand and by driving mesenchymal-to-epithelial transition [PMID:17167768, PMID:18375392, PMID:29736411, PMID:39644827]. CEACAM5 modulates immune surveillance by engaging CEACAM1 on NK cells to inhibit cytotoxicity, by activating CD8+ suppressor T cells through CD8α and CD1d binding, and by serving as a receptor for bacterial pathogens including H. pylori HopQ and Afa/Dr adhesins that exploit it for CagA translocation and colonization [PMID:15905509, PMID:24104458, PMID:27748768, PMID:27171273]. Transcription of CEACAM5 is regulated by HIF1α and the pioneer factor ASCL1 through chromatin remodeling at its promoter [PMID:29910683, PMID:33199493].\",\n  \"teleology\": [\n    {\n      \"year\": 1983,\n      \"claim\": \"Establishing the metabolic fate of circulating CEA resolved how serum levels are regulated: the liver clears CEA via a galactose-recognizing receptor after partial desialylation, followed by lysosomal degradation.\",\n      \"evidence\": \"Isolated perfused liver experiments with ¹²⁵I-CEA and enzymatic desialylation\",\n      \"pmids\": [\"6337795\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the specific hepatic lectin receptor was not molecularly defined\", \"Whether desialylation occurs in vivo enzymatically or non-enzymatically was not resolved\"]\n    },\n    {\n      \"year\": 1987,\n      \"claim\": \"cDNA cloning revealed CEACAM5's primary structure—an Ig superfamily member with a signal peptide, N-terminal IgV-like domain, six IgC2-like domains arranged in three repeats, and a GPI-anchor signal—providing the molecular framework for all subsequent functional studies.\",\n      \"evidence\": \"Independent cDNA cloning and sequencing by three laboratories with in vitro translation and cell transfection\",\n      \"pmids\": [\"3814146\", \"3670312\", \"3033671\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Three-dimensional structure not determined at this stage\", \"GPI anchorage inferred from hydrophobic C-terminal sequence but not biochemically confirmed here\"]\n    },\n    {\n      \"year\": 1989,\n      \"claim\": \"Demonstrating that CEACAM5 mediates both homophilic (CEA-CEA) and heterophilic (CEA-NCA/CEACAM6) adhesion when expressed on cell surfaces established it as a bona fide cell adhesion molecule and explained its family-level binding versatility.\",\n      \"evidence\": \"CHO cell transfection, ⁵¹Cr-labeled aggregation assay with anti-CEA Fab' blockade; parallel polarized-cell localization studies\",\n      \"pmids\": [\"2803308\", \"2674159\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which domains mediate homophilic vs. heterophilic binding was not mapped\", \"Apical restriction mechanism not elucidated\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"The discovery that CEACAM5 (and CEACAM6 but not CEACAM1) inhibits anoikis shifted understanding from a passive adhesion molecule to an active anti-apoptotic effector, implicating it in anchorage-independent tumor survival.\",\n      \"evidence\": \"Overexpression of CEA family members in multiple cell lines with anoikis assays in suspension culture\",\n      \"pmids\": [\"10910050\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling pathway mediating anoikis inhibition was not identified\", \"Whether GPI anchorage per se is the distinguishing feature from CEACAM1 was untested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Two parallel advances revealed CEACAM5's roles in immune evasion and metastatic behavior: heterophilic binding to CEACAM1 on NK cells inhibits anti-tumor cytotoxicity, while antibody targeting of CEACAM5 N-terminal/A1B1 domains suppresses tumor migration, invasion, and in vivo metastasis.\",\n      \"evidence\": \"NK killing assays with domain mutants; Matrigel invasion, endothelial adhesion, and in vivo micrometastasis model with anti-CEA Fabs\",\n      \"pmids\": [\"15905509\", \"16204051\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling pathway downstream of CEACAM1 ITIM activation by CEA not resolved\", \"Whether anti-CEA Fab effects are solely through CEACAM5 or also CEACAM6 was not fully distinguished\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identification that CEACAM5 co-clusters with integrin α5β1 to enhance fibronectin binding and matrix assembly provided the molecular mechanism for anoikis inhibition and differentiation block, validated in transgenic mice showing dose-dependent colonic hyperplasia and AKT activation.\",\n      \"evidence\": \"Confocal co-clustering, fibronectin matrix assembly assays, antibody rescue of anoikis; CEA/CEACAM6 transgenic mouse histology and phospho-AKT immunostaining\",\n      \"pmids\": [\"17167768\", \"18159236\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CEA-integrin interaction is direct or lipid raft-mediated was unresolved\", \"Transgenic model used combined CEA/CEACAM6 expression, complicating attribution to CEACAM5 alone\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"CEACAM5 was shown to carry sialofucosylated glycans that function as E/L-selectin ligands under flow, explaining how circulating tumor cells engage vascular endothelium during hematogenous metastasis; separately, soluble CEA was found to trigger CEACAM1-dependent apoptosis through caspase-1/3 activation.\",\n      \"evidence\": \"Selectin blot-rolling and flow adhesion assays with purified CEA-coated beads and CD44 knockdown cells; CEA treatment of HT29 cells with caspase and CEACAM1 cleavage analysis\",\n      \"pmids\": [\"18375392\", \"18278069\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CEA-selectin interaction is quantitatively significant relative to other selectin ligands in vivo is unknown\", \"CEACAM1-mediated apoptosis induction by CEA not confirmed outside the HT29 system\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Characterization of tumor-associated glycan modifications on CEACAM5 (Lewis X/Y, increased mannose) revealed how tumor-derived CEA engages DC-SIGN on antigen-presenting cells, linking aberrant glycosylation to immune modulation.\",\n      \"evidence\": \"Lectin capture ELISA on matched normal/tumor tissue from 48 patients\",\n      \"pmids\": [\"21823122\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of DC-SIGN engagement by tumor CEA on immune response not tested\", \"Whether glycan changes are specific to CEACAM5 or general tumor-associated modifications unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identification of CEACAM5 as the ligand for CD8α (through its N-domain, glycosylation-dependent) and CD1d (through its B3 domain) established its role in activating CD8+ suppressor T cells, providing a direct mechanism for CEA-mediated adaptive immune suppression in the gut.\",\n      \"evidence\": \"Domain deletion binding assays, Lck activation assays, T-cell suppression co-cultures with IL-15/IL-7\",\n      \"pmids\": [\"24104458\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance of CEA-CD8α/CD1d interaction for tumor immune evasion not demonstrated\", \"Structural basis of the glycosylation-dependent CD8α binding not resolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Crystal structures of H. pylori HopQ bound to CEACAM N-domains and in vivo CEA-transgenic mouse models demonstrated that CEACAM5 serves as a receptor exploited by pathogens: HopQ binding enables CagA translocation, while Afa/Dr adhesins suppress epithelial exfoliation to promote colonization.\",\n      \"evidence\": \"X-ray crystallography, KD measurements, CagA phosphorylation in CEACAM-reconstituted cells, CEA-transgenic vs. wildtype mouse colonization models\",\n      \"pmids\": [\"27748768\", \"27748756\", \"27171273\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CEACAM5 versus CEACAM1/6 is the dominant receptor for HopQ in vivo is unresolved\", \"Downstream signaling events in the epithelial cell upon bacterial CEACAM5 engagement are incompletely mapped\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Transcriptional regulation of CEACAM5 was linked to HIF1α (with FBW7 as negative regulator) and separately to promotion of mesenchymal-to-epithelial transition at metastatic sites, connecting CEA upregulation under hypoxia to metastatic outgrowth.\",\n      \"evidence\": \"ChIP and luciferase assays for HIF1α binding to CEACAM5 promoter; in vivo serial passaging gain-of-function screen with gene expression profiling and patient tissue validation\",\n      \"pmids\": [\"29910683\", \"29736411\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether HIF1α regulation of CEACAM5 operates in normal colon epithelium or only in tumor context is unknown\", \"Mechanism by which CEACAM5 drives MET gene expression program not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"ASCL1-driven chromatin remodeling at the CEACAM5 promoter was identified as the mechanism of CEACAM5 expression in neuroendocrine prostate cancer, expanding its relevance beyond adenocarcinomas to neuroendocrine lineages.\",\n      \"evidence\": \"ATAC-seq, neuroendocrine transdifferentiation assay, PDX models, antibody-drug conjugate treatment\",\n      \"pmids\": [\"33199493\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ASCL1-CEACAM5 axis operates in other neuroendocrine tumors is untested\", \"Functional role of CEACAM5 specifically in neuroendocrine cancer biology (vs. as a therapeutic target) is unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Discovery that CEACAM5 directly binds KRT1 to activate PI3K/AKT signaling provided a new mechanism for drug resistance, with a small-molecule inhibitor (evacetrapib) able to disrupt this interaction and restore oxaliplatin sensitivity.\",\n      \"evidence\": \"Co-IP, GST pull-down, SPR, immunofluorescence colocalization, organoid and xenograft models\",\n      \"pmids\": [\"39644827\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"CEA-KRT1 interaction confirmed in gastric cancer only; generalizability to other CEACAM5-expressing cancers unknown\", \"Structural basis of CEA-KRT1 binding not determined\", \"Evacetrapib selectivity for CEA-KRT1 vs. other targets requires validation\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for CEACAM5's multivalent interactions (homophilic, CEACAM1, CD8α, CD1d, KRT1), how GPI-anchored CEACAM5 transmits intracellular signals in the absence of a cytoplasmic domain, and whether its immune-modulatory functions (NK inhibition, CD8+ T-cell suppression, DC-SIGN engagement) cooperate in vivo to shape anti-tumor immunity.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No full-length CEACAM5 structure available\", \"Signaling intermediates linking GPI-anchored CEA to integrin/AKT activation remain unidentified\", \"In vivo immune evasion models combining multiple CEA-immune receptor axes are lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [1, 7, 8, 21]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [6, 10, 11]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [7, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 2, 7, 8]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [4, 8, 18]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [20]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [1, 7, 8]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [6, 10, 13, 18]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 19, 23]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [5, 8, 15, 23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CEACAM1\",\n      \"CEACAM6\",\n      \"ITGA5\",\n      \"KRT1\",\n      \"CD8A\",\n      \"CD1D\",\n      \"SERPINB5\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}